WO2000059884A1 - Pharmaceutically active compounds and methods of use thereof - Google Patents

Pharmaceutically active compounds and methods of use thereof Download PDF

Info

Publication number
WO2000059884A1
WO2000059884A1 PCT/US2000/001968 US0001968W WO0059884A1 WO 2000059884 A1 WO2000059884 A1 WO 2000059884A1 US 0001968 W US0001968 W US 0001968W WO 0059884 A1 WO0059884 A1 WO 0059884A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
methyl
pyrimidin
optionally
substimted
Prior art date
Application number
PCT/US2000/001968
Other languages
French (fr)
Inventor
Andre Rosowsky
Original Assignee
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana-Farber Cancer Institute, Inc. filed Critical Dana-Farber Cancer Institute, Inc.
Priority to EP20000907039 priority Critical patent/EP1154997A4/en
Priority to CA002361734A priority patent/CA2361734A1/en
Priority to JP2000609396A priority patent/JP2002541144A/en
Priority to US09/890,112 priority patent/US7056911B1/en
Publication of WO2000059884A1 publication Critical patent/WO2000059884A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to pharmaceutically active compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds.
  • Compounds of the invention are particularly useful for the treatment or prophylaxis of diseases associated with parasitic infection, such as toxoplasmosis, cryptosporidiosis, leischmaniasis and malaria.
  • toxoplasmosis caused by the parasitic protozoan Toxoplasma gondii, is a leading cause of morbidity and morality in patients with AIDS as well as in other immunocompromised patients such as persons receiving immunosuppressive cancer chemotherapy.
  • Toxoplasmosis also is suffered by the developing fetus with the potential result of severe neurological damage.
  • the disease is also problematic for livestock and other domesticated animals. For example, toxoplasmosis causes spontaneous abortion in sheep.
  • Pneumocytis pneumonia, cryptosporidiosis, leischmaniasis and malaria also result from parasitic infection and can be difficult to treat, particularly in immunocompromised subjects.
  • Pneumocytis pneumonia results from infection by Pnemocystis carinii, a fungal parasite which is benign in immunocomponent individuals but can be life-threatening in patients with AIDS.
  • Cryptosporidiosis results from infection of protozoa of the genus Cryptosporidium and, in the case of immunocompromised individuals, the disease can be chronic and life threatening.
  • Leischmaniasis is any of a group of conditions resulting from Leishmania infection. Manifestations of leischmaniasis are significantly enhanced in the immunocompromised. Malaria can result from infection of several different parasites: Plasmodium vivax, P.falciparum, P. malarie, and P. ovale. See generally The Merck Manual, 16 th edition.
  • That combination drug therapy has clear shortcomings. Many patients exhibit severe allergic reactions to sulfa drugs, and the therapy must be discontinued prior to effective treatment of the disease.
  • Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic;
  • W is a chemical bond, optionally substituted amino (e.g. -NH-), an optionally substituted alkylene group preferably having 1 to about 3 carbons, more preferably 1 or 2 carbon atoms such as -CH 2 - or -CH 2 CH 2 -, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms (e.g. -CH 2 NH-);
  • X is nitrogen or carbon;
  • Z represents a chemical bond (i.e. a direct bridge to provide a carbazole), optionally substituted methylene or ethylene (i.e. optionally substituted -CH 2 - or
  • Z represents hydrogens or other non-linked substituents on each phenyl group (i.e. Z is not a bridge group to thereby provide a diphenylamine);
  • each R 1 and R 2 independently may be halogen; amino; hydroxy; nitro; azido; optionally substituted alkyl preferably having 1 to about 12 carbon atoms; optionally substituted alkenyl preferably having 2 to about 12 carbon atoms; optionally substituted alkynyl preferably having 2 to about 12 carbon atoms; optionally substituted alkoxy preferably having 1 to about 12 carbon atoms; optionally substituted aminoalkyl preferably having 1 to about 12 carbon atoms; optionally substituted alkanoyl optionally having 1 to about 12 carbon atoms; optionally substituted alkylthio preferably having 1 to about 12 carbon atoms; optionally substituted alkylsulfmyl preferably having 1 to about 12 carbon atoms; optionally substituted alkylsulfonyl preferably having 1 to about 12 carbon atoms; optionally substituted carbocyclic aryl; or optionally substituted heteroaromatic or heteroalicyclic preferably having from 1 to 3 separate or fused rings and
  • Z in the above Formula I can be non-linked hydrogen or other substituents on each phenyl group, such as compounds of the following Formula
  • Preferred compounds of the invention include those of Formula I where W is optionally substituted alkylene, particularly C ⁇ - 3 alkylene, or optionally substituted nitrogen, even more preferably compounds of the following Formula II or IIA:
  • Preferred compounds of the invention also include those where the aryl group (Ar) is a single or fused group, such as compounds of the following Formula III:
  • T, U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;
  • each R 3 is independently selected from the same group of substituents as identified above for R 1 and R 2 ; or two R 3 groups on adjacent ring atoms are taken together to form a fused carbocyclic aryl, heteroaromatic, cycloalkyl or heteroalicyclic ring having from 5 to about 7 ring member,
  • o is an integer of from 0 (where the ring is fully hydrogen substituted) to 5;
  • W, X, R 1 , R 2 , m and n are each the same as defined above for Formula I; and pharmaceutically acceptable salts thereof.
  • Particularly preferred compounds of the invention include those of the following
  • U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;
  • Z, X, W, R 1 , R 2 , m and n are each the same as defined above for Formula I; and pharmaceutically acceptable salts thereof.
  • compounds of the invention are useful for a number of therapeutic applications.
  • the invention includes methods for treatment and/or prophylaxis of parasitic related diseases, including diseases or disorders associated with Toxoplasma gondii, Pneumocystis carinii, Cryptosporidium including Cryptosporidium parvum, Leishmania, Plasmodium vivax, P. falciparum, P. malarie, and/or P. ovale infections.
  • Compounds of the invention also will be useful for treatment and/or prophylaxis against tuberculosis, particularly in immunocompromised patients, such as AIDS patients, who may have enhanced susceptibility to tuberculosis.
  • the treatment methods of the invention in general comprise administration of a therapeutically effective amount of a compound of the invention to a patient in need thereof.
  • Compounds of the invention are especially useful for treatment of a mammal, particularly a primate such as a human, suffering from or susceptible to toxoplasmosis.
  • Compounds of the invention also are useful for treatment of a mammal, particularly a primate such as a human, suffering from or susceptible to other parasite-related diseases and disorders such as cryptosporidiosis, leischmaniasis and malaria.
  • Compounds of the invention are particularly useful for treatment of subjects that are susceptible to such parasitic related disorders and diseases, i.e. prophylactic treatment.
  • compounds of the invention may be administered as prophylactic treatment to AIDS patients and patients receiving immunosuppressive cancer treatments, who are particularly susceptible to toxoplasmosis, cryptosporidiosis, leischmaniasis and other parasitic related disorders and diseases.
  • references herein to "treatment,” “therapy,” or the like are inclusive of treating a subject that is suffering from a targetted disease or disorder, as well as prophylactic treatment, i.e. treating a subject that may be susceptible to such a disorder or disease.
  • Particularly preferred compounds of the invention exhibit inhibition activity in a standard dihydrofolate reductase assay e.g. as disclosed in Example 72 which follows.
  • References herein to a "standard dihydrofolate reductase assay" refer to an assay of the protocol set forth in that Example 72 which follows, and which includes spectrophotometric assay of dihydrofolate redutase without test compound (control) and then such assay of dihydrofolate redutase in the presence of varying concentrations of test compound.
  • compounds of the invention can exhibit potent and selective anti-parasitic activity upon administration to a subject due to the presence of the two fused or unfused phenyl groups (i.e. the phenyl groups that are optionally substituted by R 1 and R 2 in Formula I above). See, for instance, the results set forth in Example 72 which follows. More particularly, it is believed that one of those phenyl groups can interact hydrophobically with lipophilic amino acid residues in the active site of dihydrofolate reductase in both the parasite and host, only the active site of the parasite enzyme is sufficiently spacious to accommodate both phenyl groups of compounds of the invention, thereby providing for selective treatment against the parasite.
  • the invention also provides pharmaceutical compositions that comprise one or more compounds of the invention and a suitable carrier for the compositions.
  • Preferred compounds of the invention are amino pyrimidine compounds, particularly 2.4-diaminopyrimidine and condensed 2,4-diaminopyrimidine compounds.
  • Alkyl groups of compounds of the invention typically have from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms, or still more preferably 1, 2 or 3 carbon atoms.
  • alkyl unless otherwise modified refers to both cyclic and noncyclic groups, although of course cyclic groups will comprise at least three carbon ring members.
  • alkenyl and alkynyl groups of compounds of the invention have one or more unsaturated linkages and typically from 2 to about 12 carbon atoms, more preferably 2 to about 8 carbon atoms, still more preferably 2 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms.
  • alkenyl and alkynyl as used herein refer to both cyclic and noncyclic groups, although straight or branched noncyclic groups are generally more preferred.
  • Preferred alkoxy groups of compounds of the invention include groups having one or more oxygen linkages and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms.
  • Preferred alkylthio groups of compounds of the invention include those groups having one or more thioether linkages and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylthio groups having 1, 2, 3 or 4 carbon atoms are particularly preferred.
  • Preferred alkylsulfmyl groups of compounds of the invention include those groups having one or more sulfoxide (SO) groups and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylsulfmyl groups having 1, 2, 3 or 4 carbon atoms are particularly preferred.
  • Preferred alkylsulfonyl groups of compounds of the invention include those groups having one or more sulfonyl (SO 2 ) groups and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylsulfonyl groups having 1, 2, 3 or 4 carbon atoms are particularly preferred.
  • Preferred aminoalkyl groups include those groups having one or more primary, secondary and/or tertiary amine groups, and from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms.
  • Secondary and tertiary amine groups are generally more preferred than primary amine moieties.
  • Suitable heteroaromatic groups of compounds of the invention contain one or more N, O or S atoms and 1-3 separate or fused rings and include, e.g., coumarinyl including 8- coumarinyl, quinolinyl including 8-quinolinyl, pyridyl, pyrazinyl, pyrimidyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, oxidizolyl, triazole, imidazolyl, indolyl, benzofuranyl and benzothiazol.
  • Optionally substituted pteridine is a particularly preferred Ar group of compounds of Formula I, IA, II, and III (i.e.
  • Suitable heteroalicyclic groups of compounds of the invention contain one or more N, O or S atoms and 1-3 separate or fused rings and include, e.g., tetrahydrofuranyl, thienyl, tetrahydropyranyl, piperidinyl, morpholino and pyrrolindinyl groups.
  • Suitable carbocyclic aryl groups of compounds of the invention include single and multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups.
  • Typical carbocyclic aryl groups of compounds of the invention contain 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms.
  • Specifically preferred carbocyclic aryl groups include phenyl; naphthyl including 1 -naphthyl and 2-naphthyl; biphenyl; phenanthryl; anthracyl; and acenaphthyl.
  • Suitable aralkyl groups of compounds of the invention include single and multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups.
  • Typical aralkyl groups contain 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms.
  • Preferred aralkyl groups include benzyl and methylenenaphthyl (-CH 2 -naphthyl), and other carbocyclic aralkyl groups, as discussed above.
  • W groups of Formulae I, IA, III, IV and IVA suitably are optionally substituted C ⁇ - alkylene, more preferably CH 2 or CH 2 CH 2 , or an optionally substituted amino such as -NH-, -NH(CH 3 )-, etc., or optionally substituted aminoalkylene such as -CH 2 NH-, -NHCH 2 -, -CH 2 CH 2 NH-, -NHCH 2 CH 2 -, or - CH- 2 NHCH2-. carbon atoms, still more preferably 1, 2 or 3 carbon atoms.
  • Particularly preferred Z groups of Formula I, II, IIA, III, IV and IVA include
  • Specifically preferred compounds of the invention include the following:
  • a suitable aryl compound (Ar group precursor) linked to W group precursor that has a reactive carbon e.g. a carbon substituted with a suitable leaving group such as halogen e.g. Br or I
  • a suitable leaving group such as halogen e.g. Br or I
  • an optionally substituted carbazole may be reacted in the presence a molar excess of sodium hydride with a haloalkylaryl compound.
  • aryl compound e.g. an aminoaryl or alkylaminoaryl compound
  • X is a hetero atom
  • a phenoxazine, phenothiazine or phenazine can be reacted under similar conditions.
  • a diphenylamine can be reacted to provide compounds of Formula IA. See the examples which follow for exemplary reaction conditions.
  • preferred compounds of the invention exhibit good inhibition activity in a standard dihydrofolate reductase assay.
  • preferred compounds of the invention exhibit in a standard dihydrofolate reductase assay an IC 5 o(:M) of less than about 50 against rat liver dihydrofolate reductase, and other mammalian including human dihydrofolate reductase; more preferably an IC 50 (:M) of less than about 25 against rat liver dihydrofolate reductase, and other mammalian including human dihydrofolate reductase; even more preferably an IC 50 (:M) of less than about 10 against rat liver dihydrofolate reductase, and other mammalian including human dihydrofolate reductase.
  • Preferred compounds of the invention also include those that exhibit in a standard dihydrofolate reductase assay an IC 50 (:M) of less than about 20 against P. carinii dihydrofolate reductase, more preferably an IC 50 (:M) of less than about 10 against P. carinii dihydrofolate reductase, still more preferably an IC 5 0 (:M) of less than about 5 against P. carinii dihydrofolate reductase, even more preferably an IC 5 0 (:M) of less than about 1 or 2 against P. carinii dihydrofolate reducfase.
  • Preferred compounds of the invention also exhibit in a standard dihydrofolate reductase assay an IC 50 (:M) of less than about 10 against T. gondii dihydrofolate reductase, more preferably an IC 50 (:M) of less than about 5 against T. gondii dihydrofolate reductase, still more preferably an IC 50 (:M) of less than about 1 against T. gondii dihydrofolate reductase, even more preferably an IC 50 (:M) of less than about 0.1 against T. gondii dihydrofolate reductase.
  • Particularly preferred compounds of the invention include those compounds that exhibit selective activity for a targeted disorder or microorganism relative to activity against host proliferative tissue (e.g. bone marrow, oral/intestinal mucosa and the like).
  • host proliferative tissue e.g. bone marrow, oral/intestinal mucosa and the like.
  • Compounds of the invention may be used in therapy in conjunction with other medicaments.
  • compounds of the invention may be administered in combination with agents used for treatment against parasitic infections and associated diseases and disorders.
  • compounds of the invention can be administered in conjunction with a sulfa drug such as sulfacetamide, sulfadiazine, sulfadimethoxine, sulfadimidine, sulfamethoxazole, sulfathiazole, sulfaguanidine and the like.
  • preferred compounds of the invention will be sufficiently potent to enable effective therapy without use of another active pharmaceutical agent.
  • Compounds of the invention can be suitably administered to a subject by a variety of routes including oral, parenteral (including intraperitoneal, subcutaneous, intravenous, intradermal or intramuscular injection), topical (including trasdermal, buccal or sublingal), or nasal. Administration also suitably may be via inhalation or rectally.
  • the optimal dose can be determined by conventional means.
  • Compounds of the present invention are suitably administered to a subject in the protonated and water-soluble form, e.g., as a pharmaceutically acceptable salt of an organic or inorganic acid, e.g., hydrochloride, sulfate, hemi-sulfate, phosphate, nitrate, acetate, oxalate, citrate, maleate, mesylate, etc., or if an acid group is present on the therapeutic compound, a base addition salt can be employed, e.g. a Na or K salt.
  • an organic or inorganic acid e.g., hydrochloride, sulfate, hemi-sulfate, phosphate, nitrate, acetate, oxalate, citrate, maleate, mesylate, etc.
  • a base addition salt can be employed, e.g. a Na or K salt.
  • Compounds of the invention can be employed, either alone or in combination with one or more other therapeutic agents as discussed above, as a pharmaceutical composition in mixture with conventional excipient, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, oral, enteral, topical or intranasal application which do not deleteriously react with the active compounds and are not deleterious to the recipient thereof.
  • conventional excipient i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, oral, enteral, topical or intranasal application which do not deleteriously react with the active compounds and are not deleterious to the recipient thereof.
  • Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, etc.
  • the pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously react with the active compounds.
  • auxiliary agents e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously react with the active compounds.
  • solutions preferably oily or aqueous solutions as well as suspensions, emulsions, or implants, including suppositories.
  • Ampules are convenient unit dosages.
  • tablets, dragees or capsules having talc and/or carbohydrate carrier binder or the like are particularly suitable, the carrier preferably being lactose and/or corn starch and/or potato starch.
  • a syrup, elixir or the like can be used wherein a sweetened vehicle is employed.
  • Sustained release compositions can be formulated including those wherein the active component is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc.
  • the compounds of this invention are particularly useful in the treatment of mammalian subjects, e.g. primates particularly humans, to provide treatment from infection a variety of microorganisms including Toxoplasma gondii, Pnemocytis carinii, Cryptosporidium including Cryptosporidium parvum, Leishmania, Plasmodium vivax, P. falciparum, P. malarie, and P. ovale.
  • Such subjects include those afflicted with toxoplasmosis, cryptosporidiosis, leischmaniasis or malaria.
  • Such subjects often will be immunocompromised, e.g. the subjects may suffer a primary infection from a retrovirus such as human immunoTleficiency virus.
  • the patients also may be immunocompromised as a result of other circumstances, e.g. due to cancer therapy.
  • Compounds of the invention also will be useful for veterinary applications, e.g. to treat mammals such as livestock e.g. cattle, sheep, goats, cows, swine and the like and dogs and cats and other pets and domesticated animals; poultry such as chickens, ducks, geese, turkeys and the like.
  • the compounds will be useful to treat animals that may carry T. gondii such as sheep, pigs and cats. It will be appreciated that the actual preferred amounts of active compounds used in a given therapy will vary according to the specific compound being utilized, the particular compositions formulated, the mode of application, the particular site of administration, etc.
  • a suitable effective dose of one or more compounds of Formulae I, IA, II, IIA, III, IN, IVA will be in the range of from 0.01 to 100 milligrams per kilogram of bodyweight of recipient per day, preferably in the range of from 0.01 to 20 milligrams per kilogram bodyweight of recipient per day, more preferably in the range of 0.05 to 4 milligrams per kilogram bodyweight of recipient per day.
  • the desired dose is suitably administered once daily, or several sub-doses, e.g. 2 to 4 sub-doses, are administered at appropriate intervals through the day, or other appropriate schedule.
  • Powdergd NaH (50 mg, 2.1 mmol) is added to a stirred solution of diphenylamine (1.3 g, 0.77 mmol) in dry THF (10 mL) at 0 °C under N2. After 10 min, 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol) is added and the reaction mixture is allowed to come to room temperature and left to stir for 2 days. The excess NaH is decomposed with MeOH (1 mL) and"the mixture is concentrated to dryness by rotary evaporation.
  • Step 2 The 2,4-bis(pivaloylamino) compound (2.6 g, 7.5 mmol) obtained in Step 1 is dissolved in CHCI3 (600 mL), and the solution is cooled to 0 °C and treated with N-bromosuccinimide (1.6 g, 9.0 mmol) and benzoyl peroxide (0.2 g, 0.8 mmol). The solution is stirred overnight at room temperature, treated with additional N-bromosuccinimide (9.1 g, 51 mmol) and benzoyl peroxide (1.2 g, .4.8 mmol), and left to stir for a total of 6 days.
  • N-bromosuccinimide 1.6 g, 9.0 mmol
  • benzoyl peroxide 0.2 g, 0.8 mmol
  • Step 3 A mixture of 2,4-bis(pivaloylamino)-5-bromomethyl-6- bromothieno[2,3--
  • Step 4 To remove the pivaloyl groups, 2,4-bis(pivaloylamino)-5-(N,N- diphenylaminomethyl)-6-bromothieno[2,3- ⁇ i]pyrimidine prepared in Step 3 above (224 mg, 0.4 mmol) is stirred in a mixture of MeOH (100 mL) and 1 N NaOH (50 mL) at 35 °C overnight. The precipitated solid is collected, washed with H2O, and air-dried.
  • Step 5 To remove the remaining bromine atom, a solution of the compound prepared in Step 4 above (118 mg, 0.3 mmol) in 1:1 THF-H2O (30 mL) is cooled to 0 °C and treated with PdC_2 (240 mg, 0.6 mmol) and NaBH4 (110 mg, 3.0 mmol). The mixture is left to stir at room temperature for 8 hrs, the THF is evaporated under reduced pressure and replaced with an equal volume of H2O, and the product is extracted several times with CHCI3. The combined organic layers are dried over Na2SO4 and evaporated, and the residue is purified by silica gel chromatography using a mixture of CHCI3 and MeOH as the eluent to afford the desired compound,
  • Example 15 N-[(2,4-Diaminopyrido[2,3-J
  • Example 18 N-[(2,4-Diaminothieno[2,3-J
  • the product can be purified by chromatography.
  • Example 23 N-[(2,4-Diaminopyrido[3,2- ⁇ T
  • pyrimidin-6-yl)methyl]-9,10- dihydroacridine (Formula I: Ar 2,4-diaminopyrido[3,2--
  • pyrimidi-5-yl; W CH2;
  • the final product and its intermediates can be purified by chromatography.
  • Example 29 9-[(2,4-Diaminopyrido[2,3--
  • the product can be purified by chromatography.
  • 6-yl)methyl]-N,N-diphenylamine as disclosed above by starting from phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6- bromomethylpyrido[2,3-d]pyrimidine hydrobromide (100 mg, 0.3 mmol).
  • the product can be purified by chromatography.
  • the final product and its intermediates can be purified by chromatography.
  • Example 40 9-[(2,4-Diaminofuro[2,3--
  • Example 43 9-[(2,4-Diaminopyrido[2,3-J
  • Z CH2CH2;
  • 9,10- dihydrodibenz[b j ]azepine 158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol) and 2,4- diamino-6-bromomethylpyrido[2,3--/]pyrimidine hydrobromide (100 mg, 0.3 mmol).
  • the product can be purified by chromatography.
  • the product can be purified by chromatography.
  • the final product and its intermediates can be purified by
  • Example 47 9-[(2,4-Diaminofuro[2,3-J]pyrimidin-5-yl)methyl]-9,10- dihydrodibenz-[bj ] azepine
  • Ar 2,4-diaminofuro[2,3-cdpyrimidin-5-yl
  • W CH
  • X N
  • Z CH 2 CH 2
  • 9,10-dihydrodibenz[b j /]azepine 158 mg, 0.8 mmol
  • sodium hydride 50 mg, 2.1 mmol
  • -pyrimidine 60 mg, 0.3 mmol).
  • the product can be purified by chromatography.
  • the product can be purified by chromatography.
  • the product can be purified by chromatography.
  • Example 52 9-[(2,4-Diaminoquinazolin-6-yl)methyl]dibenz[b
  • the final product and its intermediates can be purified by chromatography.
  • the product can be purified by chromatography.
  • Example 55 9-[(2,4-Diaminopyrimidin-6-yl)methyl]dibenz[b
  • Example 56 N-(2,4-Diaminopyrido[2,3--f
  • Jjpyrimidin-6-yl)amino]fluorene as disclosed above by using 5H- dibenzo[a,-i]cycloheptan-5-one (416 mg, 2.0 mmol), 2,4-diamino-5- aminomethylpyrimidine (278 mg, 2.0 mmol), and B ⁇ 3 ⁇ -3N (75 mg, 6.6 mmol).
  • the product can be purified by chromatography.
  • Example 68 5-[N-(2,4-Diaminopyrido[2,3--i]pyrimidin-6-yl)--mino]-5H- dibenzo[ ⁇ , ⁇
  • Example 71 5-[N-[2-(2,4-Diaminopyrimidin-5-yl)ethyl]amino]-5H- dibenzo[--,-f
  • DHFR dihydrofolate reductase
  • IC 50 values were determined, which is the concentration (:M) of a compound required to inhibit the dihydrofolate reductase activity by 50%. Selectivity ratios are also set forth in the table.
  • the DHFR inhibition assay was conducted by the procedures disclosed in Broughton, M.C. et al., Antimicrob. Agents Chemother., 1991, 35: 1348- 1355; Chio, L.C. et al., Antimicrob. Agents Chemother., 1993, 37: 1914-1923. Results are set forth in Table 1 below, with the tested compound identified by reference to the structural formula set forth at the top of the table.
  • azepine inhibited the proliferation of T. gondii cells in culture as measured by a standard assay based on [ 3 H]uracil incorporation into the acid-insoluble fraction.
  • the assay protocol is disclosed in Chio, L.C. et al., Antimicrob. Agents Chemother., 1993, 37: 1914-1923. Incorporation relative to untreated controls was inhibited by 90% at a concentration of N-[2,4-diaminopteridin-6-yl)methyldibenz[b j ]azepine of 1 micromolar and the IC 50 was about 0.3 micromolar.
  • a typical IC 50 for current antixoplasmosis clinic agent pyrimethamine in this assay is 0.5-0.8 micromolar. It thus appears that N-[2,4- diaminopteridin-6-yl)methyldibenz[b l azepine is at least as active as pyrimethamine in this assay.
  • the ratio IC 50 (uracil incorporation)/IC 50 (DHFR inhibition) can indicate the efficiently of drug uptake by a parasite. In the case of the clinical agent pyrimethamine, this ratio is about 1.7. In the case of N-[2,4-diaminopteridin-6- yl)methyldibenz[b/]azepine, whose IC 50 (DHFR inhibition) is 0.045 micromolar and whose IC 50 (uracil incorporation) is about 0.3 micromolar, the ratio calculated from these data is 6.7. That indicates that the uptake of N-[2,4-diaminopteridin-6- yl)methyldibenz[b j ]azepine is about four times more efficient than that of pyrimethamine.
  • N-[2,4-diaminopteridin-6-yl)methyldibenz[b j ]azepine is also active against intact P. carinii cells as measured by a different assay based on incorporation of [ 3 H]para-aminobenzoic acid (PAB A) into the total cellular folate pool of freshly harvested cells from a rat.
  • PAB A para-aminobenzoic acid
  • the assay protocol that was employed is described in Kovacs, J.A., et al., J. Infect. Dis., 1989, 160: 312-320; and Chio, L.C. et al., Antimicrob. Agents Chemother., 1993, 37: 1914-1923. This assay can be used as measure of cell viability after drug treatment, and relies on the fact that P.
  • carinii do not take up exogenous folates but can make their own folates de novo from PABA.
  • N-[2,4-diaminopteridin-6- yl)methyldibenz[b j ]azepine there was about a 60% decrease in uptake of [ 3 H]PABA relative to controls. From this data, it can be estimated that the growth inhibitory concentration of N-[2,4-di--minopteridin-6-yl)methyldibenz[b, ]azepine against P. carinii in an established culture is about 10 micromolar or less depending on the length of treatment.
  • Example 74 Inhibition of dihyrofolate reductase (DHFR) from Mycobacterium avium
  • DHFR dihydrofolate reductase
  • M. avium Mycobacterium avium
  • IC 50 values were determined, which is the concentration (:M) of a compound required to inhibit the specified dihydrofolate reductase activity by 50%.
  • Selectivity ratios also are were determined and set forth in the table, which are calculated as the ratio of IC 5 o rat liver to IC 50 M.avium.
  • the DHFR inhibition assay was conducted by the procedures disclosed in Broughton, M.C. et al., Antimicrob.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The invention relates to pharmaceutically active compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for the treatment or prophylaxis of diseases associated with parasitic infection such as toxoplasmosis, cryptosporidiosis, leischmaniasis and malaria.

Description

PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OFUSE
THEREOF
This invention was made with government support under Grant No. RO1A129904 awarded by the National Institutes of Health. The government has certain rights in this invention.
BACKGROUND OF THE INVENTION 1. Field of the Invention
The present invention relates to pharmaceutically active compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for the treatment or prophylaxis of diseases associated with parasitic infection, such as toxoplasmosis, cryptosporidiosis, leischmaniasis and malaria.
2. Background
Parasitic-related diseases are highly prevalent and often difficult to treat. For example, toxoplasmosis, caused by the parasitic protozoan Toxoplasma gondii, is a leading cause of morbidity and morality in patients with AIDS as well as in other immunocompromised patients such as persons receiving immunosuppressive cancer chemotherapy. Toxoplasmosis also is suffered by the developing fetus with the potential result of severe neurological damage. The disease is also problematic for livestock and other domesticated animals. For example, toxoplasmosis causes spontaneous abortion in sheep.
Pneumocytis pneumonia, cryptosporidiosis, leischmaniasis and malaria also result from parasitic infection and can be difficult to treat, particularly in immunocompromised subjects. Pneumocytis pneumonia results from infection by Pnemocystis carinii, a fungal parasite which is benign in immunocomponent individuals but can be life-threatening in patients with AIDS. Cryptosporidiosis results from infection of protozoa of the genus Cryptosporidium and, in the case of immunocompromised individuals, the disease can be chronic and life threatening. Leischmaniasis is any of a group of conditions resulting from Leishmania infection. Manifestations of leischmaniasis are significantly enhanced in the immunocompromised. Malaria can result from infection of several different parasites: Plasmodium vivax, P.falciparum, P. malarie, and P. ovale. See generally The Merck Manual, 16th edition.
Current therapies to treat toxoplasmosis and other parasitic infections have included use of trimethoprim and pyrimethamine. See Merck Index 8169 and 9840 (12th edition.). However, these agents are often not sufficiently potent to be fully effective when used alone and, consequently, the agents are typically administered in combination with a sulfa drug.
That combination drug therapy, however, has clear shortcomings. Many patients exhibit severe allergic reactions to sulfa drugs, and the therapy must be discontinued prior to effective treatment of the disease.
It thus would be desirable to have new therapies to treat parasitic related diseases, such as toxoplasmosis, cryptosporidiosis, leischmaniasis and malaria.
SUMMARY OF THE INVENTION
I have now found new compounds that exhibit significant anti-parasitic activity and will be useful to treat subjects suffering from or susceptible to various parasitic related disorders and diseases, including but not limited to toxoplasmosis, cryptosporidiosis, leischmaniasis and/or malaria.
More specifically, in a first aspect, compounds of the following Formula I are provided:
Figure imgf000004_0001
wherein Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic; W is a chemical bond, optionally substituted amino (e.g. -NH-), an optionally substituted alkylene group preferably having 1 to about 3 carbons, more preferably 1 or 2 carbon atoms such as -CH2- or -CH2CH2-, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms (e.g. -CH2NH-);
X is nitrogen or carbon; Z represents a chemical bond (i.e. a direct bridge to provide a carbazole), optionally substituted methylene or ethylene (i.e. optionally substituted -CH2- or
-CH2CH2-), optionally substituted vinyl (i.e. optionally substituted -CH=CH-), optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents hydrogens or other non-linked substituents on each phenyl group (i.e. Z is not a bridge group to thereby provide a diphenylamine);
each R1 and R2 independently may be halogen; amino; hydroxy; nitro; azido; optionally substituted alkyl preferably having 1 to about 12 carbon atoms; optionally substituted alkenyl preferably having 2 to about 12 carbon atoms; optionally substituted alkynyl preferably having 2 to about 12 carbon atoms; optionally substituted alkoxy preferably having 1 to about 12 carbon atoms; optionally substituted aminoalkyl preferably having 1 to about 12 carbon atoms; optionally substituted alkanoyl optionally having 1 to about 12 carbon atoms; optionally substituted alkylthio preferably having 1 to about 12 carbon atoms; optionally substituted alkylsulfmyl preferably having 1 to about 12 carbon atoms; optionally substituted alkylsulfonyl preferably having 1 to about 12 carbon atoms; optionally substituted carbocyclic aryl; or optionally substituted heteroaromatic or heteroalicyclic preferably having from 1 to 3 separate or fused rings and with 1 to 3 hetero (N, O or S) atoms; m and n are each independently an integer of from 0 (where a ring is fully- hydrogen substituted) to 4; and pharmaceutically acceptable salts thereof.
As discussed above, Z in the above Formula I can be non-linked hydrogen or other substituents on each phenyl group, such as compounds of the following Formula
Figure imgf000006_0001
wherein in Formula IA, Ar, X, W, R and R" are the same as defined above for Formula I; and m and n are each independently an integer of from 0 (where a ring is fully-hydrogen substituted) to 5; and pharmaceutically acceptable salts thereof.
Preferred compounds of the invention include those of Formula I where W is optionally substituted alkylene, particularly Cι-3alkylene, or optionally substituted nitrogen, even more preferably compounds of the following Formula II or IIA:
Figure imgf000006_0002
wherein in Formulae II and IIA, Ar, Z, R1, R", m and n are each the same as defined above for Formula I; and pharmaceutically acceptable salts thereof.
Preferred compounds of the invention also include those where the aryl group (Ar) is a single or fused group, such as compounds of the following Formula III:
Figure imgf000006_0003
wherein in Formula III, T, U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;
each R3 is independently selected from the same group of substituents as identified above for R1 and R2; or two R3 groups on adjacent ring atoms are taken together to form a fused carbocyclic aryl, heteroaromatic, cycloalkyl or heteroalicyclic ring having from 5 to about 7 ring member,
o is an integer of from 0 (where the ring is fully hydrogen substituted) to 5;
W, X, R1, R2, m and n are each the same as defined above for Formula I; and pharmaceutically acceptable salts thereof.
Particularly preferred compounds of the invention include those of the following
Figure imgf000007_0001
wherein in each of Formulae IV and IVA, U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;
Z, X, W, R1, R2, m and n are each the same as defined above for Formula I; and pharmaceutically acceptable salts thereof.
As mentioned above, compounds of the invention (i.e. compounds of Formulae I, I A, ll, IIA, III, IN and IVA) are useful for a number of therapeutic applications. In particular, the invention includes methods for treatment and/or prophylaxis of parasitic related diseases, including diseases or disorders associated with Toxoplasma gondii, Pneumocystis carinii, Cryptosporidium including Cryptosporidium parvum, Leishmania, Plasmodium vivax, P. falciparum, P. malarie, and/or P. ovale infections. Compounds of the invention also will be useful for treatment and/or prophylaxis against tuberculosis, particularly in immunocompromised patients, such as AIDS patients, who may have enhanced susceptibility to tuberculosis. The treatment methods of the invention in general comprise administration of a therapeutically effective amount of a compound of the invention to a patient in need thereof.
Compounds of the invention are especially useful for treatment of a mammal, particularly a primate such as a human, suffering from or susceptible to toxoplasmosis. Compounds of the invention also are useful for treatment of a mammal, particularly a primate such as a human, suffering from or susceptible to other parasite-related diseases and disorders such as cryptosporidiosis, leischmaniasis and malaria.
Compounds of the invention are particularly useful for treatment of subjects that are susceptible to such parasitic related disorders and diseases, i.e. prophylactic treatment. For instance, compounds of the invention may be administered as prophylactic treatment to AIDS patients and patients receiving immunosuppressive cancer treatments, who are particularly susceptible to toxoplasmosis, cryptosporidiosis, leischmaniasis and other parasitic related disorders and diseases. Unless otherwise indicated, references herein to "treatment," "therapy," or the like are inclusive of treating a subject that is suffering from a targetted disease or disorder, as well as prophylactic treatment, i.e. treating a subject that may be susceptible to such a disorder or disease.
Particularly preferred compounds of the invention exhibit inhibition activity in a standard dihydrofolate reductase assay e.g. as disclosed in Example 72 which follows. References herein to a "standard dihydrofolate reductase assay" refer to an assay of the protocol set forth in that Example 72 which follows, and which includes spectrophotometric assay of dihydrofolate redutase without test compound (control) and then such assay of dihydrofolate redutase in the presence of varying concentrations of test compound.
Without being bound by theory, it is believed compounds of the invention can exhibit potent and selective anti-parasitic activity upon administration to a subject due to the presence of the two fused or unfused phenyl groups (i.e. the phenyl groups that are optionally substituted by R1 and R2 in Formula I above). See, for instance, the results set forth in Example 72 which follows. More particularly, it is believed that one of those phenyl groups can interact hydrophobically with lipophilic amino acid residues in the active site of dihydrofolate reductase in both the parasite and host, only the active site of the parasite enzyme is sufficiently spacious to accommodate both phenyl groups of compounds of the invention, thereby providing for selective treatment against the parasite.
The invention also provides pharmaceutical compositions that comprise one or more compounds of the invention and a suitable carrier for the compositions.
Other aspects of the invention are disclosed infra.
DETAILED DESCRIPTION OF THE INVENTION
As discussed above, we have now discovered that compounds of the following Formula I, IA, II, IIA, III, IV and IVA (i.e. compounds of the invention) are useful for therapeutic applications, particularly against parasitic-related diseases and disorders.
Figure imgf000009_0001
Figure imgf000010_0001
wherein Ar, W, X, Z, R , R", R3, T, U, V, m, n and o are as defined above.
Preferred compounds of the invention are amino pyrimidine compounds, particularly 2.4-diaminopyrimidine and condensed 2,4-diaminopyrimidine compounds.
Suitable halogen substituent groups of compounds of Formulae I, IA, II, IIA,
III, IN and IN A, as defined above (i.e. compounds of the invention) include F, Cl, Br and I. Alkyl groups of compounds of the invention typically have from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms, or still more preferably 1, 2 or 3 carbon atoms. As used herein, the term alkyl unless otherwise modified refers to both cyclic and noncyclic groups, although of course cyclic groups will comprise at least three carbon ring members. Preferred alkenyl and alkynyl groups of compounds of the invention have one or more unsaturated linkages and typically from 2 to about 12 carbon atoms, more preferably 2 to about 8 carbon atoms, still more preferably 2 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms. The terms alkenyl and alkynyl as used herein refer to both cyclic and noncyclic groups, although straight or branched noncyclic groups are generally more preferred. Preferred alkoxy groups of compounds of the invention include groups having one or more oxygen linkages and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms. Preferred alkylthio groups of compounds of the invention include those groups having one or more thioether linkages and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylthio groups having 1, 2, 3 or 4 carbon atoms are particularly preferred. Preferred alkylsulfmyl groups of compounds of the invention include those groups having one or more sulfoxide (SO) groups and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylsulfmyl groups having 1, 2, 3 or 4 carbon atoms are particularly preferred. Preferred alkylsulfonyl groups of compounds of the invention include those groups having one or more sulfonyl (SO2) groups and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylsulfonyl groups having 1, 2, 3 or 4 carbon atoms are particularly preferred. Preferred aminoalkyl groups include those groups having one or more primary, secondary and/or tertiary amine groups, and from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms. Secondary and tertiary amine groups are generally more preferred than primary amine moieties. Suitable heteroaromatic groups of compounds of the invention contain one or more N, O or S atoms and 1-3 separate or fused rings and include, e.g., coumarinyl including 8- coumarinyl, quinolinyl including 8-quinolinyl, pyridyl, pyrazinyl, pyrimidyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, oxidizolyl, triazole, imidazolyl, indolyl, benzofuranyl and benzothiazol. Optionally substituted pteridine is a particularly preferred Ar group of compounds of Formula I, IA, II, and III (i.e. in Formula III U and V are each nitrogen, and two R3 groups are taken together to form a pteridine group), particularly pteridine substituted at the 6 position to the W group linkage. Suitable heteroalicyclic groups of compounds of the invention contain one or more N, O or S atoms and 1-3 separate or fused rings and include, e.g., tetrahydrofuranyl, thienyl, tetrahydropyranyl, piperidinyl, morpholino and pyrrolindinyl groups. Suitable carbocyclic aryl groups of compounds of the invention include single and multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups. Typical carbocyclic aryl groups of compounds of the invention contain 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms. Specifically preferred carbocyclic aryl groups include phenyl; naphthyl including 1 -naphthyl and 2-naphthyl; biphenyl; phenanthryl; anthracyl; and acenaphthyl.
Suitable aralkyl groups of compounds of the invention include single and multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups. Typical aralkyl groups contain 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms. Preferred aralkyl groups include benzyl and methylenenaphthyl (-CH2-naphthyl), and other carbocyclic aralkyl groups, as discussed above. As discussed above, W groups of Formulae I, IA, III, IV and IVA suitably are optionally substituted Cι- alkylene, more preferably CH2 or CH2CH2, or an optionally substituted amino such as -NH-, -NH(CH3)-, etc., or optionally substituted aminoalkylene such as -CH2NH-, -NHCH2-, -CH2CH2NH-, -NHCH2CH2-, or - CH-2NHCH2-. carbon atoms, still more preferably 1, 2 or 3 carbon atoms. Particularly preferred Z groups of Formula I, II, IIA, III, IV and IVA include
-CH2-, -CH2CH2-, -CH=CH-, NH, O and S, with -CH=CH- being particularly preferred.
Specifically preferred compounds of the invention include the following:
N-(2,4-diaminopteridin-6-yl)methyl-N,N-diphenylamine; 2,4-diamino-6-(carbazol-5-yl)methylpteridine; 2,4-diamino-6-(9, 10-dihydroacridin-9-yl)methylpteridine;
N-[(2,4-diaminopteridin-6-yl)methyl]phenoxazine;
N-[(2,4-diaminopteridin-6-yl)methyl]phenothiazine;
N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[b, ]azepine; N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[bj ]azepine;
N-[(2,4-diaminopyrido[2,3-J]pyrimidin-6-yl)methyl]-N,N-diphenylamine;
N-[(2,4-diaminopyrido[3,2-J]pyrimidin-6-yl)methyl]-N,N-diphenylamine;
N-[(2,4-diaminoquinazolin-6-yl)methyl]-N,N-diphenylamine;
N-[(2,4-diaminothieno[2,3-cf]pyrimidin-5-yl)methyl]-N,N-diphenylamine;
N-[(2,4-diaminofuro[2,3--t pyrimidin-5-yl)methyl]-N,N-diphenylamine;
N-[(2,4-diaminopyrimidin-6-yl)methyl-N,N-diphenylamine;
N-[(2,4-diaminopteridin-6-yl)methyl]carbazole;
N-[(2,4-diaminopyrido[2,3-- ]pyrimidin-6-yl)methyl]carbazole;
N-[(2,4-diaminopyrido[3,2-J]pyrimidin-6-yl)methyl]carbazole;
N-[(2,4-diaminoquinazolin-6-yl)methyl]carbazole;
N-[(2,4-diaminothieno[2,3--i]pyrimidin-5-yl)methyl]carbazole;
N-[(2,4-diaminofuro[2,3---]pyrimidin-5-yl)methyl]carbazole;
N-[(2,4-diaminopyrimidin-6-yl)methyl]carbazole;
N-[(2,4-diaminopteridin-6-yl)methyl]-9, 10-dihydroacridine; N-[(2,4-diaminopyrido[2,3-cTlpyrimidin-6-yl)methyl]-9,10-dihydroacridine;
N-[(2,4-diaminopyrido[3,2--f|pyrimidin-6-yl)methyl]-9,10-dihydroacridine;
N-[(2,4-diaminoquinazolin-6-yl)methyl]-9, 10-dihydroacridine;
N-[(2,4-diaminothieno[2,3-- ]pyrimidin-5-yl)methyl]-9,10-dihydroacridine; N-[(2,4-diaminofuro[2,3-J]pyrimidin-5-yl)methyl]-9,10-dihydroacridine;
N-[(2,4-diaminopyrimidin-6-yl)methyl]-9, 10-dihydroacridine;
N-[(2,4-diaminopteridin-6-yl)methyl]phenoxazine;
9-[(2,4-diaminopyrido[2,3-J|pyrimidin-6-yl)methyl]phenoxazine;
9-[(2,4-diaminopyrido[3,2-J]pyrimidin-6-yl)methyl]phenoxazine;
9-[(2,4-diaminoquinazolin-6-yl)methyl]phenoxazine;
9-[(2,4-diaminothieno[2,3- ]ρyrimidin-5-yl)methyl]phenoxazine;
9-[(2,4-diaminofuro[2,3-J]pyrimidin-5-yl)methyl]phenoxazine;
9-[(2,4-diaminopyrimidin-6-yl)methyl]phenoxazine;
N-[(2,4-diaminopteridin-6-yl)methyl]phenothiazine;
9-[(2,4-diaminopyrido[2,3-J]pyrimidin-6-yl)methyl]phenothiazine;
9-[(2,4-diaminopyrido[3,2-tf|pyrimidin-6-yl)methyl]phenothiazine;
9-[(2,4-diaminoquinazolin-6-yl)methyl]phenothiazine;
9-[(2,4-diaminothieno[2,3-J]pyrimidin-5-yl]phenothiazine;
9-[(2,4-diaminofuro[2,3--/]pyrimidin-5-yl)methyl]phenothiazine;
9-[(2,4-diaminopyrimidin-5-yl)methyl]phenothiazine;
N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[bj ]azepine;
N-[(2,4-diaminopyrido[2,3- ]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz[bj ]azepine;
N-[(2,4-diaminopyrido[3,2-J]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz[bj ]azepine; 9-[(2,4-diaminoquinazolin-6-yl)methyl]-9,10-dihydrodibenz[b! ]azepine;
9-[(2,4-diaminothieno[2,3-- ]ρyrimidin-5-yl)methyl]-9,10-dihydrodibenz[b2 ]azepine;
9-[(2,4-di--min furo[2,3- ]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz[bJ/]azepine;
9-[(2,4-di--minopyrimidin-5-yl)methyl]-9,10-dihydrodibenz[b jazepine; N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[bj ]azepine;
9-[(2,4-diaminopyrido[2,3--/]pyrimidin-6-yl)methyl]dibenz[bj ]azepine;
9-[(2,4-di--minopyrido[3,2--i]pyrimidin-6-yl)methyl]dibenz[bj ]azepine;
9-[(2,4-diaminoquinazolin-6-yl) methyl]dibenz[bj ]azepine;
9-[(2,4-diaminothieno[2,3-J]pyrimidin-5-yl)methyl]dibenz[bj ]azepine;
9-[(2,4-diaminofuro[2,3-- |pyrimidin-5-yl)methyl]dibenz[bj ]azepine;
9- [(2 ,4-di aminopyrimidin-6-y l)methyl] dibenz[b f azepine;
N-(2,4-diaminopyrido[2,3-J]pyrimidin-6-yl)benzhydrylamine;
N-(2,4-diaminoquinazolin-6-yl)benzhydrylamine;
N-[(2,4-diaminopyrimidin-5-yl)methyl]benzhydrylamine;
N-[(2,4-diaminopyrimidin-5-yl)ethyl]benzhydryl-ιmine;
9-[N-(2,4-diaminoquinazolin-6-yl)amino]fluorene;
9-[N-(2,4-diaminoquinazolin-5-yl)methylamino]fluorene;
9-[N-[2-(2,4-diaminoquinazolin-5-yl)ethyl]amino]fluorene; 5-[N-(2,4-diaminopyrido[2,3-J]pyrimidin-6-yl)amino]-5H-10,l l-dihydro- dibenzo[--,cT]cycloheptene;
5- N-(2,4-diaminoquinazolin-6-yl)amino]-5H-10,l 1 - dihydrodibenzo[α,-/]cycloheptene;
5-[N-(2,4-diaminopyrimidin-5-yl)methylamino]-5H- 10, 11 -dihydrodibenzo [--,- jcycloheptene;
5-[N-[2-(2,4-diaminopyrimidin-5-yl)ethyl]amino]-5H- 10, 11 -dihydrodibenzo [α,J]cycloheptene;
5- N-(2,4-diaminopyrimidin-[2,3-- |pyrimidin-6-yl)amino]-5H-dibenzo [α,<i]cycloheptene; 5-[N-(2,4-diaminoquinazolin-6-yl)amino]-5H-dibenzo [α,-- cyclohep-ene; 5-[N-(2,4-diaminopyrimidin-5-yl)methylamino]-5H-dibenzo[α,cT|cycloheptene; and
5-[N-[2-(2,4-diaminopyrimidin-5-yl)ethyl]amino]-5H-dibenzo[Ω,-f|cycloheptene; and
pharmaceutically acceptable salts thereof.
Compounds of the invention may be readily prepared. For instance, a suitable aryl compound (Ar group precursor) linked to W group precursor that has a reactive carbon (e.g. a carbon substituted with a suitable leaving group such as halogen e.g. Br or I) can be reacted in the presence of a hydride or other suitable base with a fused ring compound, or a diphenyl amine to provide compounds of the invention. Thus, for example, to synthesize compounds of Formula I where Z is a chemical bond and W is alkylene, an optionally substituted carbazole may be reacted in the presence a molar excess of sodium hydride with a haloalkylaryl compound. To synthesize compounds where W is optionally substituted amino or aminoalkylene, the corresponding aryl compound can be employed, e.g. an aminoaryl or alkylaminoaryl compound, can be employed. To prepare compounds where X is a hetero atom, a phenoxazine, phenothiazine or phenazine can be reacted under similar conditions. A diphenylamine can be reacted to provide compounds of Formula IA. See the examples which follow for exemplary reaction conditions.
As discussed above, preferred compounds of the invention exhibit good inhibition activity in a standard dihydrofolate reductase assay. In particular, preferred compounds of the invention exhibit in a standard dihydrofolate reductase assay an IC5o(:M) of less than about 50 against rat liver dihydrofolate reductase, and other mammalian including human dihydrofolate reductase; more preferably an IC50 (:M) of less than about 25 against rat liver dihydrofolate reductase, and other mammalian including human dihydrofolate reductase; even more preferably an IC50 (:M) of less than about 10 against rat liver dihydrofolate reductase, and other mammalian including human dihydrofolate reductase.
Preferred compounds of the invention also include those that exhibit in a standard dihydrofolate reductase assay an IC50 (:M) of less than about 20 against P. carinii dihydrofolate reductase, more preferably an IC50 (:M) of less than about 10 against P. carinii dihydrofolate reductase, still more preferably an IC50 (:M) of less than about 5 against P. carinii dihydrofolate reductase, even more preferably an IC50 (:M) of less than about 1 or 2 against P. carinii dihydrofolate reducfase. Preferred compounds of the invention also exhibit in a standard dihydrofolate reductase assay an IC50 (:M) of less than about 10 against T. gondii dihydrofolate reductase, more preferably an IC50 (:M) of less than about 5 against T. gondii dihydrofolate reductase, still more preferably an IC50 (:M) of less than about 1 against T. gondii dihydrofolate reductase, even more preferably an IC50 (:M) of less than about 0.1 against T. gondii dihydrofolate reductase.
Particularly preferred compounds of the invention include those compounds that exhibit selective activity for a targeted disorder or microorganism relative to activity against host proliferative tissue (e.g. bone marrow, oral/intestinal mucosa and the like).
Compounds of the invention may be used in therapy in conjunction with other medicaments. For example, compounds of the invention may be administered in combination with agents used for treatment against parasitic infections and associated diseases and disorders. For instance, compounds of the invention can be administered in conjunction with a sulfa drug such as sulfacetamide, sulfadiazine, sulfadimethoxine, sulfadimidine, sulfamethoxazole, sulfathiazole, sulfaguanidine and the like. However, preferred compounds of the invention will be sufficiently potent to enable effective therapy without use of another active pharmaceutical agent.
Compounds of the invention can be suitably administered to a subject by a variety of routes including oral, parenteral (including intraperitoneal, subcutaneous, intravenous, intradermal or intramuscular injection), topical (including trasdermal, buccal or sublingal), or nasal. Administration also suitably may be via inhalation or rectally. The optimal dose can be determined by conventional means.
Compounds of the present invention are suitably administered to a subject in the protonated and water-soluble form, e.g., as a pharmaceutically acceptable salt of an organic or inorganic acid, e.g., hydrochloride, sulfate, hemi-sulfate, phosphate, nitrate, acetate, oxalate, citrate, maleate, mesylate, etc., or if an acid group is present on the therapeutic compound, a base addition salt can be employed, e.g. a Na or K salt.
Compounds of the invention can be employed, either alone or in combination with one or more other therapeutic agents as discussed above, as a pharmaceutical composition in mixture with conventional excipient, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, oral, enteral, topical or intranasal application which do not deleteriously react with the active compounds and are not deleterious to the recipient thereof. Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, etc. The pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously react with the active compounds.
For parenteral application, particularly suitable are solutions, preferably oily or aqueous solutions as well as suspensions, emulsions, or implants, including suppositories. Ampules are convenient unit dosages.
For enteral application, particularly suitable are tablets, dragees or capsules having talc and/or carbohydrate carrier binder or the like, the carrier preferably being lactose and/or corn starch and/or potato starch. A syrup, elixir or the like can be used wherein a sweetened vehicle is employed. Sustained release compositions can be formulated including those wherein the active component is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc.
As discussed above, the compounds of this invention are particularly useful in the treatment of mammalian subjects, e.g. primates particularly humans, to provide treatment from infection a variety of microorganisms including Toxoplasma gondii, Pnemocytis carinii, Cryptosporidium including Cryptosporidium parvum, Leishmania, Plasmodium vivax, P. falciparum, P. malarie, and P. ovale. Such subjects include those afflicted with toxoplasmosis, cryptosporidiosis, leischmaniasis or malaria. Such subjects often will be immunocompromised, e.g. the subjects may suffer a primary infection from a retrovirus such as human immunoTleficiency virus. The patients also may be immunocompromised as a result of other circumstances, e.g. due to cancer therapy.
Compounds of the invention also will be useful for veterinary applications, e.g. to treat mammals such as livestock e.g. cattle, sheep, goats, cows, swine and the like and dogs and cats and other pets and domesticated animals; poultry such as chickens, ducks, geese, turkeys and the like. In particular, the compounds will be useful to treat animals that may carry T. gondii such as sheep, pigs and cats. It will be appreciated that the actual preferred amounts of active compounds used in a given therapy will vary according to the specific compound being utilized, the particular compositions formulated, the mode of application, the particular site of administration, etc. Optimal administration rates for a given protocol of administration can be readily ascertained by those skilled in the art using conventional dosage determination tests conducted with regard to the foregoing guidelines. In general, a suitable effective dose of one or more compounds of Formulae I, IA, II, IIA, III, IN, IVA, will be in the range of from 0.01 to 100 milligrams per kilogram of bodyweight of recipient per day, preferably in the range of from 0.01 to 20 milligrams per kilogram bodyweight of recipient per day, more preferably in the range of 0.05 to 4 milligrams per kilogram bodyweight of recipient per day. The desired dose is suitably administered once daily, or several sub-doses, e.g. 2 to 4 sub-doses, are administered at appropriate intervals through the day, or other appropriate schedule.
All documents mentioned herein are incorporated herein by reference in their entirety. The following non-limiting examples are illustrative of the invention.
Example 1 : Ν-(2,4-Diaminopteridin-6-yl)methyl-Ν,Ν-diphenylamine
(Formula I: Ar = 2,4-diaminopteridin-6-yl); X = N; W = CH2; Z = non-linked hydrogens on each phenyl group; m = n = 0).
Powdergd NaH (50 mg, 2.1 mmol) is added to a stirred solution of diphenylamine (1.3 g, 0.77 mmol) in dry THF (10 mL) at 0 °C under N2. After 10 min, 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol) is added and the reaction mixture is allowed to come to room temperature and left to stir for 2 days. The excess NaH is decomposed with MeOH (1 mL) and"the mixture is concentrated to dryness by rotary evaporation. Flash chromatography on silica gel with 95:5 CHC^-MeOH as the eluent affords the product, N-(2,4-diaminopteridin-6- yl)methyl-N,N-diphenylamine, as a bright-yellow powder (56 mg, 54% yield); mp >250 °C dec; MS (FAB) m/z (M + 1) = 344; IR (KBr) v 3450, 3340, 3170, 1630, 1590, 1550, 1490, 1450, 1360, 1220 cm"1; ΪH NMR (rf6-DMSO) δ 5.10 (s, 2H, CH2), 6.70 (m, 10H, aromatic), 8.60 (s, 1H, C7-H. Anal. Calcd for Ci9H17N7-0.8H2O: C, 63.73; H, 5.23; N, 27.40. Found: C, 64.15; H, 4.85; N, 27.07.
Example 2: Preparation of 2,4-Diamino-6-(carbazol-5-yl)methylpteridine
(Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH2; Z=chemical bond; m=n=0).
NaH (60% oil suspension containing 44 mg. 1.88 mmol) was added to a stirred solution of carbazole (65.5 mg, 0.392 mmol) in dry THF (10 mL) at 0°C under N2. After 10 minutes, 2,4-diamino-6-bromo-methylpteridine hydrobromide (100 mg, 0.392 mmol) was added and the reaction mixture was allowed to come to room temperature and left to stir for 2 days. The excess NaH was decomposed with several drops of MeOH followed by three drops of glacial AcOH, and the mixture was concentrated to dryness by rotary evaporation. Flash chromatography on silica gel with 85:15 CHCl3-MeOH followed by 1:1 CHCl3-MeOH as the eluent. Appropriate fractions were pooled and evaporated to a yellow solid which was dried in vacuo at 70°C overnight, to provide the title compound, 2,3-diamino-6-(carbazol-5- yl)methylpteridine, yield 10 mg (<10%). MS (FAB) m/z (M + 1) = 342.2265. Anal. Calcd. for Cι9H15N7 1/6CHC13: C, 63.72; H, 4.23. Found: C, 63.41; H, 4.11.
Example 3: Preparation of 2,4-Diamino-6-(9,10-dihydroacridin-9- yl)methylpteridine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH2; Z=CH ; m=n=0).
Raney Ni (1 g) was added to a solution of acridine (1 g, 5.58 mmol) in EtOH (20 mL), and the mixture was shaken under a hydrogen atmosphere (50 psi) for 2 days. Additional EtOH (200 mL) was added, and the Ni catalyst was removed by filtration. Evaporation of filtrate and recrystallization of the residue from MeOH afforded colorless needles of 5,10-dihydroacridine (0.7 g, 70% yield); mp 169-170°C. A portion of this material (0.224 g. 1.18 mmol) was dissolved in dry THF (10 mL) under N2, and the solution was cooled to 0 °C, and NaH (50% oil suspension containing 0.119 g, 4.7 mmol) was added in small portions with magnetic stirring. After 10 min, 2,4-diamino-6-bromomethylpteridine hydrobromide (0.100 g, 0.392 mmol) was added slowly with continued stirring, and the reaction mixture was allowed to warm to room temperature and stirred overnight. Excess sodium hydride was destroyed with a small drops of AcOH, and the solvents were removed by rotary evaporation. Flash chromatography of the residue on silica gel with 9: 1 ChCl3-MeOH as the eluent afforded the title compound, 2,4-diamino-6-(9,10-dihydroacridin-9- yl)methylpteridine, as a yellow-brown solid (ca. 10% yield); mp>250 °C dec. MS (FAB m/z (M + 1) = 370.1785.
Example 4: Preparation of N-[(2,4-Diaminopteridin-6-yl)methyl]phenoxazine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH2; Z=O; m=n=0).
NaH (60% oil suspension containing 51 mg, 2.0 mmol) was added to a stirred solution of phenoxazine (147 mg, 0.784 mmol) in dry THF (10 mL) at 0 °C under N2. After 10 min. 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg. 0.392 mmol) was added and the reaction mixture was allowed to come to room temperature and left to stir for 2 days. The excess NaH was decomposed with MeOH (1 mL), and the mixture was concentrated to dryness by rotary evaporation. Flash chromatography on silica gel yielded the title compound, N-[(2,4-diaminopteridin-6- yl)methyl]phenoxazine, as a brown solid; yield 47 mg (34%); mp >250 °C dec. Anal. Calcd. for C,9H15N7O 0.4H2O: C, 62.60; H, 4.37. Found: C, 62.84; H, 4.10. Example 5: Preparation of N-[(2,4-Diaminopteridin-6- yl)methyl]phenothiazine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH2; Z=S; m=n=0).
NaH (60% oil suspension containing 51 mg. 2.0 mmol) was added to a stirred solution of phenoxazine (159 mg, 0.784 mmol) in dry THF (20 mL) at 0°C under N2. After 10 min. 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg. 0.392 mmol) was added and the reaction mixture was allowed to come to room temperature and left in stir for 2 days. The excess NaH was decomposed with MeOH (1 mL), and the mixture was concentrated to dryness by rotary evaporation. Flash chromatography on silica gel yielded the title compound, N-[(2,4-diaminopteridin-6- yl)methyl]phenothiazine, as a greenish-yellow solid; yield 20 mg (14%); mp250 °C dec. Anal. Calcd. for Cι9H,9N7 5/5CHCl3; C, 64.73, H, 4.93, Found: C, 64.55; H 4.90.
Example 6: Preparation of N-[(2,4-Diaminopteridin-6-yl)methyl]-9,10- dihydrodibenz[b, ] azepine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH2; Z=CH2CH2; m=n=0).
NaH (60% oil suspension containing 11 mg, 0.47 mmol) was added to a stirred solution of 9,10-dihydrodibenz[b,/]azepine (77 mg. 0.392 mmol) in dry THF (10 mL) at 0 °C under N2. After 10 minutes, 2,4,diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.392 mmol) was added and the reaction mixture was allowed to come to room temperature and left to stir for 2 days. After the excess NaH was decomposed with a small volume of MeOH, the mixture was poured into H2O (20 mL) and the product extracted into 85:15 CHCl3-MeOH (3 x 50 mL). The organic layer was dried over Na2SO4 and evaporated, and the residue was purified by preparative TLC (silica gel, 85L15 CHCl3-MeOH) to obtain the title compound, N- [(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[b./]azepine, as a yellow solid (35 mg. 24% yield). Anal. Calcd. for C2-H19N7 1/5 CHC13: C, 64.73; H, 4.93. Found: C, 64.55: H, 4.90.
Example 7: Preparation of N-[(2,4-Diaminopteridin-6-yl)methyl]dibenz[b, ]
azepine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W= CH=CH; Z=CH2; m=n=0).
NaH (60% oil suspension containing 44 mg. 1.88 mmol) was added to a stirred solution of dibenz[b, ] azepine (76 mg. 0.392 mmol) in dry THF (10 mL) at 0 °C under N2. After 10 min, 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg. 0.392 mmol) was added and the reaction mixture was allowed to come to room temperature and left to stir for overnight. After the excess NaH was decomposed with MeOH (0.5 mL) and 3 drops of glacial AcOH, the mixture was poured into H2O (20 mL) and the product was extracted into 85:15 CHCl3:MeOH (3 x 5t_imL). The organic layers was dried over Na2SO4 and evaporated and the residue was purified by column chromatography (flash silica gel. 85:15 CHCl :MeOH) to obtain the title compound, N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[b,/]azepine, as a yellow solid (25 mg. 17% yield). MS (FAB) m/z = M + 1) 367.199. Anal. Calcd. for C2-Hι7N7 '/4CHC13: C,. 64.25; H, 4.38; N. 2468: Found: C, 64.06; H, 4.19, N, 23.82.
Example 8: N-[(2,4-Diaminopyrido[2,3--i]pyrimidin-6-yl)methyl]-N,N- diphenylamine (Formula I: Ar = 2,4-diamiopyrido[2,3-J]pyrimidin-6-yl); X = N; W = CH2; Z = non-linked hydrogens on each phenyl group; Z = CH2; m = n = 0) is prepared similarly as disclosed in Example 1 above by using N,N-diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3- -f]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography. Example 9: N-[(2,4-Diaminopyrido[3,2-J]pyrimidine-6-yl)methyl]-N,N- diphenylamine (Formula I: Ar = 2,4-diaminopyrido[3,2-d]pyrimidin-6-yl; X = N; W = CH2; Z = non-linked hydrogens on each phenyl group; Z = CH2; m = n = 0) is prepared similarly as disclosed in Example 1 above by using diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3- Jlpyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 10: N-[(2,4-Diaminoquinazolin-6-yl)methyl]-N,N-diphenylamine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; X = N; W = CH2; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly as disclosed in Example 1 above by using diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 11 : N-[(2,4-Diaminothieno[2,3--i]pyrimidin-5-yl)methyl]-N,N- diphenylamine (Formula I: Ar = 2,4-diaminothieno[2,3--i]pyrimidin-5-yl; W = CH2; X = N; Z = non-linked hydrogens on each phenyl group; m = n = 0). Step 1. A mixture of 2,4-diamino-5-methylthieno[2,3-J]pyrimidine
(1.3 g, 7.2 mmol) and pivalic anhydride (33 g, 18 mmol) in dry pyrMine is refluxed under N2 overnight, then cooled and evaporated under reduced pressure. The residue is taken up in E-2O (500 mL), the solution is washed with 5% NaHCU3 (2 x 100 mL), the organic layer is dried and evaporated, and the residue is recrystallized from E-2O to obtain the 2,4-bis(pivaloylamino) derivative.
Step 2. The 2,4-bis(pivaloylamino) compound (2.6 g, 7.5 mmol) obtained in Step 1 is dissolved in CHCI3 (600 mL), and the solution is cooled to 0 °C and treated with N-bromosuccinimide (1.6 g, 9.0 mmol) and benzoyl peroxide (0.2 g, 0.8 mmol). The solution is stirred overnight at room temperature, treated with additional N-bromosuccinimide (9.1 g, 51 mmol) and benzoyl peroxide (1.2 g, .4.8 mmol), and left to stir for a total of 6 days. The yellow solid which precipitates during this time is filtered off, and the filtrate is washed with H2O (2 x 50 mL), dried and evapor-ated to obtain 2,4-bis(pivaloylamino)-5-bromomethyl-6-bromothieno[2,3- Jjpyrimidine.
Step 3. A mixture of 2,4-bis(pivaloylamino)-5-bromomethyl-6- bromothieno[2,3-- |pyrimidine prepared in Step 2 above (200 mg, 0.4 mmol), diphenylamine (1.3 g, 0.77 mmol) and NaH (50 mg, 2.1 mmol) in dry THF (10 mL) is stirred at room temperature for 2 days, the excess NaH is decomposed with MeOH (1 mL), the solvent is evaporated, and the residue is chromatographed on silica gel to obtain 2,4-bis(pivaloylamino)-5-(N,N-diphenylaminomethyl)-6-bromothieno[2,3- -/jpyrimidine.
Step 4. To remove the pivaloyl groups, 2,4-bis(pivaloylamino)-5-(N,N- diphenylaminomethyl)-6-bromothieno[2,3-<i]pyrimidine prepared in Step 3 above (224 mg, 0.4 mmol) is stirred in a mixture of MeOH (100 mL) and 1 N NaOH (50 mL) at 35 °C overnight. The precipitated solid is collected, washed with H2O, and air-dried.
Step 5. To remove the remaining bromine atom, a solution of the compound prepared in Step 4 above (118 mg, 0.3 mmol) in 1:1 THF-H2O (30 mL) is cooled to 0 °C and treated with PdC_2 (240 mg, 0.6 mmol) and NaBH4 (110 mg, 3.0 mmol). The mixture is left to stir at room temperature for 8 hrs, the THF is evaporated under reduced pressure and replaced with an equal volume of H2O, and the product is extracted several times with CHCI3. The combined organic layers are dried over Na2SO4 and evaporated, and the residue is purified by silica gel chromatography using a mixture of CHCI3 and MeOH as the eluent to afford the desired compound,
N-[(2,4-diaminothieno[2,3--i]pyrimidin-6-yl)methyl]-N,N-diphenylamine. The final product and its intermediates can be purified by chromatography.
Example 12: N-[(2,4-Diaminofuro[2,3-J]pyrimidin-5-yl)methyl]-N,N- diphenylamine (Formula I: Ar = 2,4-diaminofuro[2,3-d]pyrimidin-5-yl; W = CH2; X
= N; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3--i]pyrimidin-6-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-- |pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.
Example 13 : N-[(2,4-Diaminopyrimidin-6-yl)methyl-N-N-diphenylamine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH2; X = N; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-(2,4- diaminopteridin-6-yl)methyl-N,N-diphenylamine as disclosed above by using diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5- bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmole). The product can be purified by chromatography.
Example 14: N-[(2,4-Diaminopteridin-6-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH2; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-(2,4-diaminopteridin-6-yl)methyl-N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography. Example 15: N-[(2,4-Diaminopyrido[2,3-J|pyrimidm-6-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminopyrido[2,3-d[pyrimidin-6-yl; W = CH-2; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6- yl)methyl]N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3- <i]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 16: N-[(2,4-Diaminopyrido[3,2-J]pyrimidin-6-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminopyrido[2,3-d]pyrimidin-6-yl; W = CH2; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6- yl)methyl]-N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2- Jpyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 17: N-[(2,4-Diaminoquinazolin-6-yl)methyl]carbazole (Formula I:
Ar = 2,4-diaminoquinazolin-6-yl; W = CH2;. N = X; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinaoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 18: N-[(2,4-Diaminothieno[2,3-J|pyrimidin-5-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminothieno[2,3--- pyrimidin-5-yl; W = CH2; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3- -7]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using 2,4-diamino-5-methylthieno[2,3-(f]pyrimidine (1.3 g, 7.2 mmol) in Step 1 and carbazole (129 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.
Example- 19: N-[(2,4-Diaminofuro[2,3-J]pyrimidin-5-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminofuro[2,3-J]pyrimidin-5-yl; W = CH2; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminofuro[2,3- -i]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using carbazole (129 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5- chloromethylfuro[2,3--i]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.
Example 20: N-[(2,4-Diaminopyrimidin-6-yl)methyl]carbazole (Formula I:
Ar = 2,4-diaminopyrimidin-5-yl; W = CH2; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.
Example 21 : N-[(2,4-Diaminopteridin-6-yl)methyl]-9, 10-dihydroacridine (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH2; N = X; Z = CH2; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 22: N-[(2,4-Diaminopyrido[2,3--f]pyrimidin-6-yl)methyl]-9,10- dihydroacridine (Formula I: Ar = 2,4-diaminopyrido[2,3-Jjpyrimidin-6-yl; W = CH2; X = N; Z = CH2; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6- yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6- bromomethylpyrido[2,3-d]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 23: N-[(2,4-Diaminopyrido[3,2-ύT|pyrimidin-6-yl)methyl]-9,10- dihydroacridine (Formula I: Ar = 2,4-diaminopyrido[3,2-- |pyrimidin-6-yl; W = CH2; X = N; Z = CH2; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6- yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6- bromomethylpyrido[3,2-- ]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography. Example 24: N-[(2,4-Diaminoquinazolin-6-yl)methyl]-9,10-dihydroacridine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH2; X = N; Z - CH2; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 25 : N-[(2,4-Diaminothieno[2,3-J]pyrimidin-5-yl)methyl]-9, 10- dihydroacridine (Formula I: Ar = 2,4-diaminothieno[2,3-J|pyrimidi-5-yl; W = CH2;
X = N; Z = CH2; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3- -/]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using 2,4-diamino-5-methylthieno[2,3-J|pyrimidine (1.3 g, 7.4 mmol) in Step 1 and 9,10-dihydroacridine (134 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.
Example 26: N-[(2,4-Diaminofuro[2,3-- ]pyrimidin-5-yl)methyl]-9,10- dihydroacridine (Formula I: Ar = 2,4-diaminofuro[2,3-2]pyrimidin-5-yl; W = CH2; X = N; Z = CH2; m = n = 0) is prepared similarly to N-[(2,4-diaminofuro[2,3-
-f]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4- diamino-5-chloromethylfuro[2,3-- ]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.
Example 27: N-[(2,4-Diaminopyrimidin-6-yl)methyl]-9, 10-dhydroacridine
(Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH2; X = N; Z = CH2; m = = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.
Example 28: N-[(2,4-Diaminopteridin-6-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diamiπopteridin-6-yl; W = CH2; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4- diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The final product can be purified by chromatography.
Example 29: 9-[(2,4-Diaminopyrido[2,3-- |pyrimidin-6- yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminopyrido[2,3--i]pyrimidin-6-yl; W = CH2; X = N; Z = O; m = = 0) is prepared similarly to N-[(2,4-diaminopteridin-6- yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg,0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3- _ ]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography. Example 30: 9-[(2,4-Diaminopyrido[3,2-J]pyrimidin-6- yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminopyrido[3,2--i]pyrirnidin-6-yl; W = CH2; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6- yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2- J]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 31 : 9-[(2,4-Diaminoquinazolin-6-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH2; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4- diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 32: 9-[(2,4-Diaminothieno[2,3-J]pyrimidin-5- yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminothieno[2,3--/]pyrimidin-5-yl; W = CH2; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-
-f|pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using 2,4-diamino-5-methylthieno[2,3--φyrimidine (1.3 g, 7.4 mmol) in Step 1 and phenoxazine (146 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography. Example 33 : 9-[(2,4-Diaminofuro[2,3-J]pyrimidin-5-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminofuro[2,3--f]pyrimidin-5-yl; W = CH2; C = N; Z = O; m
= n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-- ]pyrimidin-5-yl)methyl]- N,N-diphenylamine as disclosed in Example 11 above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3- --Ipyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.
Example 34: 9-[(2,4-Diaminopyrimidin-6-y-)methyl]phenoxazine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH2; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4- diamino-5-bromomethylpyridine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.
Example 35: N-[(2,4-Diaminopteridin-6-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH2 X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4- diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 36: 9-[(2,4-Diaminopyrido[2,3--i]pyrimidin-6- yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminopyrido[2,3- cT]pyrimidin-6-yl; W = CH2; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-
6-yl)methyl]-N,N-diphenylamine as disclosed above by starting from phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6- bromomethylpyrido[2,3-d]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 37: 9-[(2,4-Diaminopyrido[3,2-d]pyrimidin-6- yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminopyrido[3,2--i]pyrimidin-6-yl; W = CH2; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6- yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2- jpyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 38: 9-[(2,4-Diaminoquinazolin-6-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH2; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 39: 9-[(2,4-Diaminothieno[2,3-J]pyrimidin-5- yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminothieno[2,3-J|pyrimidin-5-yl; W = CH2; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3- - )pyrimidin-5-yl)methyl]-N,N-diphenyl-amine as disclosed in Example 11 above by using 2,4-diamino-5-methylthieno[2,3-- |pyrimidine (1.3 g, 7.4 mmol) in Step 1 and phenothiazine (159 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.
Example 40: 9-[(2,4-Diaminofuro[2,3-- |pyrimidin-5- yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminofuro[2,3--i]pyrimidin-5-yl; W = CH2; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminofuro[2,3- J]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5- chloromethylfuro[2,3-J]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.
Example 41 : 9-[(2,4-Diaminopyrimidin-5-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH2; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4- diamino-5-bromomethylpyridine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.
Example 42: N-[(2,4-Diaminopteridin-6-yl)methyl]-9,10- dihydrodibenz[bj ]azepine (Formula I: Ar = 2,4-diaminopteridiin-6-yl; W = CH2; X = N; Z = CH2CH2; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6- yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10- dihydrodibenz[b,/] azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4- diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 43: 9-[(2,4-Diaminopyrido[2,3-J|pyrimidin-6-yl)methyl]-9,10- dihydrodibenz-[bj ]azepine (Formula I: Ar = 2,4-diaminopyrido[2,3-fiT)pyrimidin-6-yl; W = CH2; X = N; Z = CH2CH2; m = n = 0) is prepared similarly to N-[(2,4- diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10- dihydrodibenz[bj ]azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol) and 2,4- diamino-6-bromomethylpyrido[2,3--/]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 44: 9-[(2,4-Diaminopyrido[3,2--/]pyrimidin-6-yl)methyl]-9, 10- dihydrodibenz-[b J azepine (Formula I: Ar = 2,4-diaminopyrido[3,2-d]pyrimidin-6-yl; W = CH2; X = N; Z = CH2CH2; m = n = 0) is prepared similarly to N-[(2,4- diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10- dihydrodibenz[b ]azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4- diamino-6-bromomethylpyrido[3,2-cT]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography. Example 45: 9-[(2,4-Diaminoquinazolin-6-yl)methyl]-9,10- dihydrodibenz[b,/]azepine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH2; X
= N; Z = CH2CH2; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6- yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10- dihydrodibenz[bj ]azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4- diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 46: 9-[(2,4-Diaminothieno[2,3-cTlpyrimidin-5-yl)methyl]-9, 10- dihydrodibenz-fbj ]azepine (Formula I: Ar = 2,4-diaminohieno[2,3-J]pyrimidi-5-yl; W = CH2; X = N; Z = CH2CH2; m = n = 0) is prepared similarly to N-[(2,4- diaminothieno[2,3-J]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 1 1 above, by using 2,4-diamino-5-methylthieno[2,3--/]pyrimidine (1.3 g, 7.4 mmol) in Step 1 and 9,10-dihydrodibenz[b, ]azepine (158 mg, 0.8 rffmol) in Step 3. The final product and its intermediates can be purified by chromatography.
Example 47: 9-[(2,4-Diaminofuro[2,3-J]pyrimidin-5-yl)methyl]-9,10- dihydrodibenz-[bj ] azepine (Formula I: Ar = 2,4-diaminofuro[2,3-cdpyrimidin-5-yl; W = CH ; X = N; Z = CH2CH2; m = n = 0) is prepared similarly to N-[(2,4- diaminofuro[2,3--f]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydrodibenz[bj/]azepine (158 mg, 0.8 mmol), sodium hydride (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-J|-pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.
Example 48 : 9-[(2,4-Diaminopyrimidin-5-yl)methyl]-9, 10- dhydrodibenzfb,/] azepine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH2; X
= N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6- yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10- dihydrodibenz[bj ]azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4- diamino-5-bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.
Example 49: N-[(2,4-Diaminopteridin-6-yl)methyl]dibenz[b Jazepine (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH2; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above, by using dibenz[b ]azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 50: 9-[(2,4-Diaminopyrido[2,3-J]pyrimidin-6- yl)methyl]dibenz[bj ] azepine (Formula I: Ar = 2,4-diaminopyrido[2,3-c ]pyrimidin-6- yl; W = CH2; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4- diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using dibenz[bj ]azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6- bromomethylpyrido[2,3-- |pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography. Example 51 : 9-[(2,4-Diaminopyrido[3,2--i]pyrimidin-6- yl)methyl]dibenz[bj ]azepine (Formula I: Ar = 2,4-diaminopyrido[--72- ]pyrimidin-6- yl; W = CH2; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4- diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using dibenz[b ]azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6- bromomethylpyrido[3,2-J]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 52: 9-[(2,4-Diaminoquinazolin-6-yl)methyl]dibenz[b |azepine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH2; X = N; Z = CH= H; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N- diphenylamine as disclosed above by using dibenz[b Jazepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.
Example 53: 9-[(2,4-Diaminothieno[2,3--i]pyrimidin-5- yl)methyl]dibenz[b Jazepine (Formula I: Ar = 2,4-diaminothieno[2,3-- |pyrimidin-5- yl; W = CH2; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4- diaminothieno[2,3-J]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed above by using 2,4-diamino-5-methylthieno[2,3-J]pyrimidine (1.3 g, 7.4 mmol) in Step 1 and dibenz[bj ] azepine (154 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.
Example 54: 9-[(2,4-Diaminofuro[2,3- ]pyrimidin-5- yl)methyl]benz[bj/]azepine (Formula I: Ar = 2,4-diaminofuro[2,3-J]pyrimidin-5-yl; W = CH2; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4- diaminofuro[2,3--i]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed above by using dibenzfb jazepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4- di--mino-5-chloromethylfuro[2,3-d[pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.
Example 55: 9-[(2,4-Diaminopyrimidin-6-yl)methyl]dibenz[b |azepine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH2; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using dibenz[b |azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.
Example 56: N-(2,4-Diaminopyrido[2,3--f|pyrimidin-6-yl)benzhydrylamine (Formula I: Ar = 2,4-di--minopyrido[2,3- yrimidin-6-yl; W = NH; X = CH; Z = non-linked hydrogens on each phenyl group; m = n = 0).
A solution of benzhydrylamine (366 mg, 2.0 mmol) and 2,4,6- triaminopyrido[2,3--i]pyrimidine (350 mg, 2.0 mmol) in a mixture of DMF (40 mL) and glacial AcOH (4 mL) is treated with BH3-E-3N (75 mg, 6.6 mmol), and the mixture is stirred at room temperature overnight, then diluted with H2O (20 mL) to decompose any umeacted reducing agent. The solvents are evaporated under reduced pressure, and the residue is purified on a silica gel column using 5-15% CHCI3 in
MeOH as the eluent. Pooling and evaporation of appropriate fractions yields the title compound, N-(2,4-diaminopyrido[2,3-J|pyrimidin-6-yl)benzhydrylamine. Example 57: N-[(2,4-Diaminoquinazolin-6-yl)amino]benzhydrylamine
(Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = NH; X = CH; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-[(2,4- diaminopyrido[2,3-J]pyrimidin-6-yl)amino]benzhydrylamine as disclosed above by using benzhydrylamine (366 mg, 2.0 mmol), 2,4,6-triaminoquinazoline (350 mg, 2.0 mmol), and BH3 E-3N (75 mg, 6.6 mmol). The product can be purified by chromatography.
Example 58: N-[(2,4-Diaminopyrimidin-5-yl)methyl]benzhydrylamine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl); W = CH2NH; X = CH; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-(2,4- diaminopyrido[2,3--/Ipyrimidin-6-yl)amino]benzhydrylamine as disclosed above by using benzhydrylamine (366 mg, 2.0 mmol), 2,4-diamino-5-aminomethylpyrimidine
(278 mg, 2.0 mmol), mg, 2 mmol), and BH3Ε-3N (75 mg, 6.6 mmol). The product can be purified by chromatography. Example 59: N-[(2,4-Diaminopyrimidin-5-yl)ethyl]benzhydrylamine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH2CH2NH; X = CH; Z = non- linked hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-(2,4- diaminopyrido[2,3-- |pyri-midin-6-yl)amino]benzhydrylamine as disclosed above by using benzhydrylamine (366 mg, 2.0 mmol), 2,4-diamino-5-(2-aminoethyl)pyrimidine
(306mg, 2.0 mmol), mg, 2.0 mmol), and BH3Ε-3N (75 mg, 6.6 mmol). The product can be purified by chromatography.
Example 60: 9-[N-(2,4-Diaminopyrido[2,3- ]pyrimidin-6-yl)amino]f-uorene (Formula I: Ar = 2,4-diaminopyrido[2,3-J]pyrimidin-6-yl; W = NH; X = CH; Z = chemical bond; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-
<--]pyrimidin-6-yl)amino]benzhydrylamine as disclosed above by using fluorenone (360 mg, 2.0 mmol), 2,4,6-triaminopyrido[2,3--f|pyrimidine (350 mg, 2.0 mmol), mg,
2.0 mmol), and BH3-E-3N (75 mg, 6.6 mmol). The product can be purified by chromatography.
Example 61 : 9-[N-(2,4-Diaminoquinazolin-6-yl)amino]fluorene (Formula I:
Ar = 2,4-diaminoquinazolin-6-yl; W = NH; Z = CH; Z = chemical bond; m = n = 0) is prepared similarly to N-(2,4-diammopyrido[3,2--f]pyrimidin-6-yι)amino]fluorene as disclosed above by using fluorenone (360 mg, 2.0 mmol), 2,4,6-triaminoquinazoline
(350mg, 2.0 mmol), and BH3Ε.3N (75 mg, 6.6 mmol). The product can be purified by chromatography.
Example 62: 9-[N-(2,4-Diaminopyrimidin-5-yl)methylamino]fluorene (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH2NH is prepared similarly to N-
(2,4-diaminopyrido-[2,3--.]pyrimidin-6-yl)amino]fluorene as disclosed above by using fluorenone (360 mg, 2.0 mmol), 2,4-diamino-5-aminomethylpyrimidine (278 mg, 2.0 mmol), and BH3Ε-3N (75 mg, 6.6 mmol). The product can be purified by chromatography.
Example 63: 9-[N-[2-(2,4-Diaminopyrimidin-5-yl)ethyl]amino]fluorene (Formula I: Ar = 2,4-diaminopyrimidin-5-yl); W = CH2CH2NH; X = CH; Z = chemical bond; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3- J]pyrimidin-6-yl)amino]fluorene as disclosed above by using fluorenone (360 mg, 2.0 mmol), 2,4-diamino-5-(2-aminoethyl)pyrimidine (306 mg, 2.0 mmόl), and BH3Ε-3N (75 mg, 6.6 mmol). The product can be purified by chromatography.
Example 64: 5-[N-(2,4-Diaminopyrido[2,3---]pyrimidin-6-yl)amino]-5H- 10,1 l-dihydro-dibenzo[ ,- ]cycloheptene (Formula I: Ar = 2,4-diaminopyrido[2,3- jpyrimidin-ό-yl; W = NΗ; X = CΗ; Z = CΗ2CΗ2; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido-[2,3--i]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5H-dibenzo[ ,-i]cycloheptene-5-one (416 mg, 2.0 mmol), 2,4,6- triaminopyrido[2,3-- ]pyrimidine (350 mg, 2.0 mmol), and BΗ3Ε-3N (75 mg, 6.6 mmol). The product can be purified by chromatography.
Example 65: 5-[N-(2,4-Diaminoquinazolin-6-yl)amino]-5H-10,l l- dihydrodibenzo[α, ]-cycloheptene (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = NΗ; X = CΗ; Z = CΗ2CΗ2; m = n = 0) is prepared similarly to N-(2,4- di_-minopyrido[2,3-- |pyrimidin-6-yl)amino]fluorene as disclosed above by using 5H- dibenzo[α,-/]cycloheptane-5-one (416 mg, 2.0 mmol), 2,4,6-triaminoquinazoline (350 mg, 2.0 mmol), and BΗ3Ε-3N (75 mg, 6.6 mmol). The product can be purified by chromatography.
Example 66: 5-[N-(2,4-Diaminopyrimidin-5-yl)methylamino]-5H- 10,11- dihydro-dibenzo[-.,-f]heptene (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CΗ2NΗ; Z = CH2CH2; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-
Jjpyrimidin-6-yl)amino]fluorene as disclosed above by using 5H- dibenzo[a,-i]cycloheptan-5-one (416 mg, 2.0 mmol), 2,4-diamino-5- aminomethylpyrimidine (278 mg, 2.0 mmol), and BΗ3Ε-3N (75 mg, 6.6 mmol). The product can be purified by chromatography.
Example 67: 5-[N-[2-(2,4-Diaminopyrimidin-5-yl)ethyl]amino]-5H-10,l l- dihydro-dibenzo[ ,-i]cycloheptene (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CΗ2CΗ2NΗ; X = CH; Z = CH=CH; m = n = 0) is prepared similarly to N-(2,4- diaminopyrido[2,3--i]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5H- dibenzo[-.,<i]cycloheptan-5-one (416 mg, 2.0 mmol), 2,4-diamino-5-(2- aminoethyl)pyrimidine (306 mg, 2.0 mmol), and BH3-E-3N (75 mg, 6.6 mmol). The product can be purified by chromatography.
Example 68: 5-[N-(2,4-Diaminopyrido[2,3--i]pyrimidin-6-yl)--mino]-5H- dibenzo[α,< |-cycloheptene (Formula I: Ar = 2,4-diaminopyrido[2,3--flpyrimidin-6-yl; W = NΗ; X = CΗ; Z = CΗ=CΗ; m = n = 0) is prepared similarly to N-(2,4- diaminopyrido[2,3-<i]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5H- dibenzo[α,(/|cyclohepten-5-one (412 mg, 2.0 mmol), 2,4,6-triaminopyrido[2,3-
J]pyrimidine (350 mg, 2.0 mmol), and BΗ3Ε.3N (75 mg, 6.6 mmol). The product can be purified by chromatography.
Example 69: 5-[N-(2,4-Diaminoquinazolin-6-yl)amino]-5H- dibenzo[-.,</]cycloheptene (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = NΗ; X = CΗ; Z = CΗ=CΗ; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3- -/]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5H- dibenzo[α,J]cycloheptan-5-one (412 mg, 2.0 mmol), 2,4,6-triaminoquinazoline (350 mg, 2.0 mmol), and BΗ3-E-3N (75 mg, 6.6 mmol). The product can be purified by chromatography.
Example 70: 5-[N-(2,4-Diaminopyrimidin-5-yl)methylamino]-5H- dibenzo[α,J]heptene (Formula I: Ar = 2,4-diaminopyrmidin-5-yl; W = CΗ2NΗ; X =
CH; Z = chemical bond; m = n = 0) is prepared similarly to N-(2,4- diaminopyrido[2,3--i]pyrimidin-6-yl)--mino]fluorene as disclosed above by using 5H- dibenzo[a,-/]cycloheptan-5-one (412 mg, 2.0 mmol), 2,4-diamino-5- aminomethylpyrimidine (278 mg, 2.0 mmol), and BΗ3 E-3N (75 mg, 6.6 mmol). The product can be purified by chromatography.
Example 71 : 5-[N-[2-(2,4-Diaminopyrimidin-5-yl)ethyl]amino]-5H- dibenzo[--,-f|heptene (Formula I: Ar = 2,4-diaminopyrimidin-5-yl); W = CΗ2CΗ2NΗ;
X = CH=CH; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3- - ]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5H- dibenzo[ ,J]cycloheptan-5-one (412 mg, 2.0 mmol), 2,4-diamino-5-(2- aminoethyl)pyrimidine (306 mg, 2.0 mmol), and BH3Ε-3N (75 mg, 6.6 mmol). The product can be purified by chromatography.
Example 72: Dihydrofolate reductase inhibition
Compounds of the invention were tested for inhibition of dihydrofolate reductase (DHFR) from rat liver, Pneumocystis carinii and Toxoplasmosis gondii. IC50 values were determined, which is the concentration (:M) of a compound required to inhibit the dihydrofolate reductase activity by 50%. Selectivity ratios are also set forth in the table. The DHFR inhibition assay was conducted by the procedures disclosed in Broughton, M.C. et al., Antimicrob. Agents Chemother., 1991, 35: 1348- 1355; Chio, L.C. et al., Antimicrob. Agents Chemother., 1993, 37: 1914-1923. Results are set forth in Table 1 below, with the tested compound identified by reference to the structural formula set forth at the top of the table.
Table 1. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and rat liver dihydrofolate reductase by compounds of the invention.
Figure imgf000040_0001
DHFR inhibition (IC so μM)c selectivity ratio cmpd X P. carinii T.gondii rat liver rat liver/ rat liver/
P. carinii T. gondii liver
1 a 4.9 1.3 2.8 0.57 2.2
2 b 0.10 0.055 0.012 0.55 0.022
3 CH2 0.042 0.029 0.027 0.64 0.93
4 O 3.4 2.2 13 3.8 5.9
5 S 0.12 0.11 0.20 1.7 1.8
6C CH2CH2 expt 1 1.7 0.89 4.4 expt 2 1.0 0.93 2.7 mean 1.4 0.91 5.1 3.6 5.6
?c CH=CH expt 1 0.24 0.010 2.1 expt 2 0.18 0.041 9.3 expt 3 0.084 4.4 mean 0.21 0.045 5.3 25 118
a No bridge between the phenyl rings (i.e. X is non-linked hydrogens)
b Direct bridge between the phenyl rings (i.e. X is a chemical bond) c Replicate assays performed on different days Example 73: Additional data of N-[2,4-diaminopteridin-6-yl)methyldibenz
[bf azepine
It was also found that N-[2,4-diaminopteridin-6-yl)methyldibenz[b |azepine inhibited the proliferation of T. gondii cells in culture as measured by a standard assay based on [3H]uracil incorporation into the acid-insoluble fraction. The assay protocol is disclosed in Chio, L.C. et al., Antimicrob. Agents Chemother., 1993, 37: 1914-1923. Incorporation relative to untreated controls was inhibited by 90% at a concentration of N-[2,4-diaminopteridin-6-yl)methyldibenz[bj ]azepine of 1 micromolar and the IC50 was about 0.3 micromolar. A typical IC50 for current antixoplasmosis clinic agent pyrimethamine in this assay is 0.5-0.8 micromolar. It thus appears that N-[2,4- diaminopteridin-6-yl)methyldibenz[b l azepine is at least as active as pyrimethamine in this assay.
The ratio IC50(uracil incorporation)/IC50 (DHFR inhibition) can indicate the efficiently of drug uptake by a parasite. In the case of the clinical agent pyrimethamine, this ratio is about 1.7. In the case of N-[2,4-diaminopteridin-6- yl)methyldibenz[b/]azepine, whose IC50 (DHFR inhibition) is 0.045 micromolar and whose IC50 (uracil incorporation) is about 0.3 micromolar, the ratio calculated from these data is 6.7. That indicates that the uptake of N-[2,4-diaminopteridin-6- yl)methyldibenz[bj ]azepine is about four times more efficient than that of pyrimethamine.
N-[2,4-diaminopteridin-6-yl)methyldibenz[bj ]azepine is also active against intact P. carinii cells as measured by a different assay based on incorporation of [3H]para-aminobenzoic acid (PAB A) into the total cellular folate pool of freshly harvested cells from a rat. The assay protocol that was employed is described in Kovacs, J.A., et al., J. Infect. Dis., 1989, 160: 312-320; and Chio, L.C. et al., Antimicrob. Agents Chemother., 1993, 37: 1914-1923. This assay can be used as measure of cell viability after drug treatment, and relies on the fact that P. carinii do not take up exogenous folates but can make their own folates de novo from PABA. After 5 hours of treatment with 17.6 micromolar N-[2,4-diaminopteridin-6- yl)methyldibenz[bj ]azepine there was about a 60% decrease in uptake of [3H]PABA relative to controls. From this data, it can be estimated that the growth inhibitory concentration of N-[2,4-di--minopteridin-6-yl)methyldibenz[b, ]azepine against P. carinii in an established culture is about 10 micromolar or less depending on the length of treatment.
Example 74: Inhibition of dihyrofolate reductase (DHFR) from Mycobacterium avium
Compounds of the invention were tested for inhibition of dihydrofolate reductase (DHFR) from Mycobacterium avium (M. avium), an organism which has been used to screen drug candidates for activity against tuberculosis. IC50 values were determined, which is the concentration (:M) of a compound required to inhibit the specified dihydrofolate reductase activity by 50%. Selectivity ratios also are were determined and set forth in the table, which are calculated as the ratio of IC5o rat liver to IC50 M.avium. The DHFR inhibition assay was conducted by the procedures disclosed in Broughton, M.C. et al., Antimicrob. Agents Chemother., 1991, 35: 1348- 1355; Chio, L.C. et al., Antimicrob. Agents Chemother., 1993, 37: 1914-1923. Results are set forth in Table 2 below, with the tested compound identified by reference to the structural formula set forth at the top of the table (substituent X specified in Table 2), IC50 values (expressed in:M) against rat liver DHFR and M. avium DHFR, followed by the selectivity index.
Table 2. Inhibition of dihydrofolate reductase from Mycobacterium avium
Figure imgf000043_0001
Cmpd X rat liver DHFR M. avium DHFR Selectivity Index
1 CH= CH 2.1 0.012 175
2 a 4.0 3.7 1.1
3 CH2 0.027 0.017 1.6
4 O 13 2.5 5.2
5 S 0.20 0.029 6.9
No bridge between the phenyl rings (i.e. X is non-linked hydrogens)
The invention has been described in detail with reference to preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements within the spirit and scope of the invention as set forth in the following claims.

Claims

What is claimed is:
1. A compound of the following Formula I:
Figure imgf000044_0001
wherein Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic;
W is a chemical bond, optionally substituted amino, optionally substimted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;
X is nitrogen or carbon;
Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substimted N, or Z represents non-linked substituents on each phenyl group; each Rl and R2 independently may be halogen, amino, hydroxy, nitro, azido. optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substimted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substimted alkylsulfmyl, optionally substimted alkylsulfonyl, optionally substimted carbocyclic aryl, or optionally substimted heteroaromatic, or optionally substimted heteroalicyclic; m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.
2. A compound of the following Formula IA:
Figure imgf000045_0001
wherein Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic;
W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;
X is nitrogen or carbon;
Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene. O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;
each R1 and R2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfmyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substimted heteroaromatic, or optionally substituted heteroalicyclic;
m and n are each independently an integer of from 0 to 5; and pharmaceutically acceptable salts thereof.
3. A compound of the following Formula II:
Figure imgf000046_0001
wherein Ar is optionally substimted carbocyclic aryl or optionally substimted heteroaromatic;
Z represents a chemical bond, optionally substimted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;
X is nitrogen or carbon; each R1 and R2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substimted alkoxy, optionally substituted aminoalkyl, optionally substimted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfmyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;
m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.
4. A compound of the following Formula IIA:
Figure imgf000046_0002
wherein Ar is optionally substimted carbocyclic aryl or optionally substimted heteroaromatic;
Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substimted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;
X is nitrogen or carbon;
each R1 and R2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substimted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfmyl, optionally substituted alkylsulfonyl, optionally substimted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;
m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.
5. A compound of the following Formula III:
Figure imgf000047_0001
T, U and V are each independently optionally substituted carbon, or optionally substimted nitrogen; W is a chemical bond, optionally substituted amino, optionally substimted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having! nitrogen and 1 or 2 carbon atoms;
X is nitrogen or carbon;
Z represents a chemical bond, optionally substimted methylene, optionally substimted ethylene, optionally substimted vinyl, optionally substimted azamethinyl, optionally substituted azamethylene, O, S, or optionally substimted N, or Z represents non-linked substituents on each phenyl group; each R1, R2 and R3 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfmyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;
m and n are each independently an integer of from 0 to 4; o is an integer of from 0 to 5 and pharmaceutically acceptable salts thereof.
6. A compound of the following Formula IV:
Figure imgf000048_0001
U and V are each independently optionally substituted carbon, or optionally substituted nitrogen; W is a chemical bond, optionally substimted amino, optionally substimted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;
X is nitrogen or carbon;
Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;
each R and R independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfmyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substimted heteroalicyclic;
m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.
7. A compound of the following Formula IVA:
Figure imgf000049_0001
U and V are each independently optionally substituted carbon, or optionally substituted nitrogen; W is a chemical bond, optionally substimted amino, optionally substituted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;
X is nitrogen or carbon;
Z represents a chemical bond, optionally substimted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group; each R1 and R2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfmyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substimted heteroalicyclic; m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.
8. A compound of any one of claims 1, 3, 4, 5, 6 or 7 wherein Z is -CH2-,
Figure imgf000050_0001
9. A compound of any one of claims 1, 2, 5, 6 or 7 wherein W is a bond, CH2, CH2CH2, or NH.
10. A compound of claim 1 wherein the compound is: N-(2,4-diaminopteridin-6-yl)methyl-N,N-diphenylamine;
2,4-diamino-6-(carbazol-5-yl)methylpteridine;
2,4-diamino-6-(9, 10-dihydroacridin-9-yl)methylpteridine; N-[(2,4-diaminσpteridin-6-yl)methyl]phenoxazine; N-[(2,4-diaminopteridin-6-yl)methyl]phenothiazine; N- [(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[b J azepine;
N- [(2,4-diaminopteridin-6-yl)methyl]dibenz[b ] azepine;
N [(2,4-diaminopyrido[2,3-J|pyrimidin-6-yl)methyl]-N,N-diphenylamine;
N- [(2,4-diaminopyrido[3,2-t/]pyrimidin-6-yl)methyl]-N,N-diphenylamine;
N- [(2,4-diaminoquinazolin-6-yl)methyl]-N,N-diphenylamine;
N [(2,4-diaminothieno[2,3--i]pyrimidin-5-yl)methyl]-N,N-diphenylamine;
N [(2,4-diaminofuro[2,3--f]pyrimidin-5-yl)methyl]-N,N-diphenylamine;
N [(2,4-diaminopyrimidin-6-yl)methyl-N,N-diphenylamine;
N- [(2,4-diaminopteridin-6-yl)methyl]carbazole;
N [(2,4-diaminopyrido[2,3--i]pyrimidin-6-yl)methyl]carbazole;
N- [(2,4-diaminopyrido[3,2-- |pyrimidin-6-yl)methyl]carbazole;
N- [(2,4-diaminoquinazolin-6-yl)methyl]carbazole;
N [(2,4-diaminothieno[2,3-J|pyrimidin-5-yl)methyl]carbazole;
N [(2,4-diaminofuro[2,3--i]pyrimidin-5-yl)methyl]carbazole;
N- [(2,4-diaminopyrimidin-6-yl)methyl]carbazole;
N- [(2,4-diaminopteridin-6-yl)methyl]-9, 10-dihydroacridine;
N- [(2,4-diaminopyrido[2,3-J]pyrimidin-6-yl)methyl]-9,10-dihydroacridine;
N [(2,4-diaminopyrido[3,2-- |pyrimidin-6-yl)methyl]-9,10-dihydroacridine;
N [(2,4-diaminoquinazolin-6-yl)methyl]-9, 10-dihydroacridine;
N [(2,4-diaminothieno[2,3--i]pyrimidin-5-yl)methyl]-9,10-dihydroacridine; N-[(2,4-diaminofuro[2,3--/]pyrimidin-5-yl)methyl]-9,10-dihydroacridine; N-[(2,4-diaminopyrimidin-6-yl)methyl]-9, 10-dihydroacridine; N-[(2,4-diaminopteridin-6-yl)methyl]phenoxazine; 9-[(2,4-diaminopyrido[2,3--/]pyrimidin-6-yl)methyl]phenoxazine;
9-[(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)methyl]phenoxazine; 9-[(2,4-diaminoquinazolin-6-yl)methyl]phenoxazine; 9- [(2 ,4-di amino thieno [2 ,3 -Jjpyrimidin- 5 -yl)me thyljphenoxazine;
9-[(2,4-diaminofuro[2,3-Jlpyrimidin-5-yl)methyl]phenoxazine;
9-[(2,4-diaminopyrimidin-6-yl)methyl]phenoxazine; N-[(2,4-diaminopteridin-6-yl)methyl]phenothiazine; 9-[(2,4-diaminopyrido[2,3- ]pyrimidin-6-y-)methyl]phenothiazine; 9-[(2,4-diaminopyrido[3,2-ύT]pyrimidin-6-yl)methyl]phenothiazine;
9-[(2,4-diaminoquinazolin-6-yl)methyl]phenothiazine; 9-[(2,4-diaminothieno[2,3-J|pyrimidin-5-yl]phenothiazine; 9-[(2,4-diaminofuro[2,3--/]pyrimidin-5-yl)methyl]phenothiazine;
9-[(2,4-diaminopyrimidin-5-yl)methyl]phenothiazine; N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[bj ] azepine; N-[(2,4-diaminopyrido[2,3--/]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz[bj ] azepine; N-[(2,4-diaminopyrido[3,2-- |pyrimidin-6-yl)methyl]-9,10-dihydrodibenz[bj ] azepine;
9-[(2,4-diaminoquinazolin-6-yl)methyl]-9,10-dihydrodibenz[bj ] azepine; 9-[(2,4-diaminothieno[2,3--t pyrimidin-5-yl)methyl]-9,10-dihydrodibenz[bj/] azepine; 9-[(2,4-diaminofuro[2,3--i]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz[bj ] azepine;
9-[(2,4-diaminopyrimidin-5-yl)methyl]-9,10-dihydrodibenz[b ] azepine; N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[bj/] azepine; 9-[(2,4-diaminopyrido[2,3-- Ipyrimidin-6-yl)methyl]dibenz[bj ] azepine; 9-[(2,4-diaminopyrido[3,2-- ]pyrimidin-6-yl)methyl]dibenz[bj ] azepine; 9-[(2,4-diaminoquinazolin-6-yl) methyl]dibenz[b ] azepine;
9-[(2,4-diaminothieno[2,3--- pyrimidin-5-yl)methyl]dibenz[bj ] azepine;
9-[(2,4-diaminofuro[2,3--i]pyrimidin-5-yl)methyl]dibenz[bj ] azepine;
9-[(2,4-diaminopyrimidin-6-yl)methyl]dibenz[bj ] azepine;
N-(2,4-diaminopyrido[2,3--i]pyrimidin-6-yl)benzhydrylamine;
N-(2,4-diaminoquinazolin-6-yl)benzhydrylamine;
N-[(2,4-diaminopyrimidin-5-yl)methyl]benzhydrylamine;
N-[(2,4-diaminopyrimidin-5-yl)ethyl]benzhydrylamine;
9-[N-(2,4-diaminoquinazolin-6-yl)amino]fluorene;
9-[N-(2,4-diaminoquinazolin-5-yl)methylamino]fluorene;
9-[N-[2-(2,4-diaminoquinazolin-5-yl)ethyl]amino]fluorene;
5-[N-(2,4-diaminopyrido[2,3-c |pyrimidin-6-yl)amino]-5H- 10,11 -dihydro- dibenzo[-.,-/]cycloheptene;
5-[N-(2,4-di--minoquinazolin-6-yl)--mino]-5H- 10, 11 - dihydrodibenzo[α,-/)cycloheptene;
5-[N-(2,4-diaminopyrimidin-5-yl)methylamino]-5H-10, 11 -dihydrodibenzo [α,cT]cycloheptene;
5-[N-[2-(2,4-diaminopyrimidin-5-yl)ethyl]amino]-5H- 10,11 -dihydrodibenzo [α, ]cycloheptene;
5-[N-(2,4-diaminopyrimidin-[2,3-J]pyrimidin-6-yl)--mino]-5H-dibenzo [ ,- ]cycloheptene;
5-[N-(2,4-diaminoquinazolin-6-yl)amino]-5H-dibenzo [α,-f]cycloheptene;
5-[N-(2,4-diaminopyrimidin-5-yl)methylamino]-5H-dibenzo[α,-i]cycloheptene; and
5-[N-[2-(2,4-diaminopyrimidin-5-yl)ethyl]amino]-5H-dibenzo[ ,Jjcycloheptene; and
pharmaceutically acceptable salts thereof.
11. A method of treating a patient suffering from or susceptible to a parasitic disease, comprising administering to the patient an effective amount of a compound of any one of claim 1-10.
12. A method of treating a patient suffering from or susceptible to toxoplasmosis, comprising administering to the patient an effective amount of a compound of any one of claim 1-10.
13. The method of claim 11 or 12 wherein the patient's immune system is suppressed.
14. The method of claim 11 or 12 wherein the patient has a retrovirus infection.
15. The method of claim 11 or 12 wherein the patient has an HIV infection.
16. The method of claim 11 or 12 wherein the patient is suffering from AIDS.
17. The method of claim 11 or 12 wherein the patient has received or will be receiving immunosuppressive cancer chemotherapy treatment.
18. A method of treating a patient suffering from or susceptible to cryptosporidiosis, leischmaniasis or malaria, comprising administering to the patient an effective amount of a compound of any one of claims 1-10.
19. A method of treating a patient suffering from or susceptible to an infection oϊ Toxoplasma gondii, Pnemocytis carinii, Cryptosporidium, Leishmania, Plasmodium vivax, P. falciparum, P. malarie, or P. ovale.
20. A method of treating a patient suffering from or susceptible to a Toxoplasma gondii infection.
21. A method of treating a patient suffering from or susceptible to tuberculosis.
22. A method of any one of claims 11-21 wherein the disease is treated without administration of a sulfa drug to the patient.
23. The method of any one of claims 11-22 wherein the patient is a mammal.
24. A method of any one of claims 11 -22 wherein the patient is a human.
25. A method of claim 11, 12 or 20 wherein the patient is a livestock animal, poultry or a domesticated animal.
26. A pharmaceutical composition a pharmaceutically acceptable carrier and a compound of any one of claims 1-10.
PCT/US2000/001968 1999-01-26 2000-01-25 Pharmaceutically active compounds and methods of use thereof WO2000059884A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP20000907039 EP1154997A4 (en) 1999-01-26 2000-01-25 Pharmaceutically active compounds and methods of use thereof
CA002361734A CA2361734A1 (en) 1999-01-26 2000-01-25 Pharmaceutically active compounds and methods of use thereof
JP2000609396A JP2002541144A (en) 1999-01-26 2000-01-25 Pharmaceutically active compounds and methods of use
US09/890,112 US7056911B1 (en) 1999-01-26 2000-01-25 Dibenz[B,F]azepine compounds, pharmaceutical compositions comprising same and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11732199P 1999-01-26 1999-01-26
US60/117,321 1999-01-26

Publications (1)

Publication Number Publication Date
WO2000059884A1 true WO2000059884A1 (en) 2000-10-12

Family

ID=22372237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001968 WO2000059884A1 (en) 1999-01-26 2000-01-25 Pharmaceutically active compounds and methods of use thereof

Country Status (5)

Country Link
US (1) US7056911B1 (en)
EP (1) EP1154997A4 (en)
JP (1) JP2002541144A (en)
CA (1) CA2361734A1 (en)
WO (1) WO2000059884A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123724A1 (en) * 2004-06-08 2005-12-29 Decode Chemistry, Inc. 2,4-diaminoquinazolines for spinal muscular atrophy
EP1852119A1 (en) * 2005-02-17 2007-11-07 Japan Science and Technology Agency Pharmaceutical composition containing phenoxazinium compound as active ingredient
US7411072B2 (en) 2002-06-26 2008-08-12 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
US7803814B2 (en) 2003-12-19 2010-09-28 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
US7985755B2 (en) 2006-08-01 2011-07-26 Families Of Spinal Muscular Atrophy 2,4-diaminoquinazolines for spinal muscular atrophy
US7994164B2 (en) 2007-12-19 2011-08-09 Eli Lilly And Company Mineralocorticoid receptor antagonists and methods of use
US8101760B2 (en) 2006-07-14 2012-01-24 Eli Lilly And Company Glucocorticoid receptor modulator and methods of use
US8101761B2 (en) 2008-01-11 2012-01-24 Eli Lilly And Company (E)-N-{3-[1-(8-fluoro-11H-10-OXA-1-AZA-dibenzo [A,D] cyclohepten-5ylidene)-propyl]-phenyl}-methanesulfonamide as glucocorticoid receptor modulator for the treatment of rheumatoid arthritis
EP2470013A1 (en) * 2009-08-27 2012-07-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Compounds that treat malaria and prevent malaria transmission
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
CN110526874A (en) * 2019-08-28 2019-12-03 武汉华星光电半导体显示技术有限公司 Fluorenes and phenazene derivative and preparation method thereof and OLED device
WO2022096990A1 (en) * 2020-11-05 2022-05-12 Cadila Healthcare Limited Novel hetrocyclic compounds

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004292992A1 (en) * 2003-11-24 2005-06-09 Georgia State University Research Foundation, Inc Fused ring dicationic anti-protozoan agents and their prodrugs
US9796720B2 (en) * 2013-08-22 2017-10-24 Bristol-Myers Squibb Company Imidazole-derived modulators of the glucocorticoid receptor
KR20230109185A (en) 2016-06-07 2023-07-19 자코바이오 파마슈티칼스 컴퍼니 리미티드 Novel heterocyclic derivatives useful as shp2 inhibitors
JP6878615B2 (en) 2017-03-23 2021-05-26 ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． A novel heterocyclic derivative useful as an SHP2 inhibitor
AU2020289459A1 (en) * 2019-06-07 2022-01-06 Elanco Tiergesundheit Ag Bicyclic derivatives for treating endoparasites

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB822592A (en) * 1956-06-27 1959-10-28 Promonta Chem Fab Carbazole derivatives and process for the production thereof
JPH06135946A (en) * 1992-10-30 1994-05-17 Otsuka Pharmaceut Co Ltd Pyrazine derivative

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE437974C (en) 1924-10-08 1926-12-02 Leopold Cassella & Co G M B H Process for the preparation of phosphorus-containing derivatives of the carbazole series
NL67220C (en) 1947-02-14
CH353740A (en) 1956-02-04 1961-04-30 Promonta Chem Fab Process for the preparation of 10- (N-alkylpiperidyl-3'-methyl) -phenthiazines
CH376920A (en) 1958-07-03 1964-04-30 Parke Davis & Co Process for preparing 10-oxides of acridinylamino-o-cresols
CH372675A (en) * 1958-07-23 1963-10-31 Geigy Ag J R Process for the production of new, basic substituted azepine derivatives
JPS63270678A (en) * 1987-04-30 1988-11-08 Mitsui Petrochem Ind Ltd Novel nitrogen-containing compound
JPH02101015A (en) * 1988-10-04 1990-04-12 Santen Pharmaceut Co Ltd Antimalarial agent
ES2142817T3 (en) * 1991-12-27 2000-05-01 Kyowa Hakko Kogyo Kk TRICYCLIC COMPOUNDS AS ANGIOTENSIN II ANTAGONISTS.
JPH08119920A (en) * 1994-10-18 1996-05-14 Kyowa Hakko Kogyo Co Ltd Tricyclic anilide derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB822592A (en) * 1956-06-27 1959-10-28 Promonta Chem Fab Carbazole derivatives and process for the production thereof
JPH06135946A (en) * 1992-10-30 1994-05-17 Otsuka Pharmaceut Co Ltd Pyrazine derivative

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"THE ROLE OF FOLIC ACID IN ONE-CARBON UNIT TRANSFER", CHEMISTRY OF PYRIMIDINES, PURINES AND PTERIDINES, XX, XX, 1 January 1980 (1980-01-01), XX, pages 168 - 171 + 241, XP002930606 *
FELDMAN ET AL.: "Some reactions of methylene-bis-amides as ammono-aldehydes", J. ORG. CHEM.,, vol. 7, January 1942 (1942-01-01), pages 31 - 47, XP002930545 *
KATRITZKY A.R. ET AL.: "Chemistry of benzotriazole. Preparation lithiation and transformation of N-(benzotriazol-1-ylmethyl) heterocycles", J. HETEROCYCL. CHEM.,, vol. 26, no. 3, 1989, pages 829 - 836, XP002930543 *
LUGOVKIN ET AL.: "Reactions of 6-(chloromethyl)quinoline with heterocyclic nitrogenous compounds", J. ORGANIC CHEM. USSR,, vol. VII, 1964, (ENGL. TRANSL), pages 1124 - 1126, XP002930546 *
PRAGST F. ET AL.: "Rearrangement of 1-amino-4-methylpyridinum ions into 4-aminomethylpyrimidines under the action of bases", Z. CHEM.,, vol. 27, no. 8, 1987, pages 289 - 290, XP002930544 *
ROSOWSKY A. ET AL.: "Structure-based design of selective inhibitors of dihydrofolate reductase: Synthesis and antiparasitic activity of 2,4-diaminopteridine analogues with a bridged diarylamine side chain", J. MED. CHEM.,, vol. 42, no. 23, 1999, pages 4853 - 4860, XP002930542 *
See also references of EP1154997A4 *
SHAFI S.S. ET AL.: "Studies on biologically active heterocycles: part II. Synthesis of 2-(1,2,3,4-tetrahydro-9-carbazolymehtyl)thiazolo(3,2-b)-s-triazol-5(6H)-one and related systems", INDIAN J. HETEROCYCL. CHEM.,, vol. 7, no. 3, 1998, pages 231 - 232, XP002930300 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411072B2 (en) 2002-06-26 2008-08-12 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
US7803814B2 (en) 2003-12-19 2010-09-28 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
US9067897B2 (en) 2004-06-08 2015-06-30 Families Of Spinal Muscular Atrophy 2,4-Diaminoquinazolines for spinal muscular atrophy
WO2005123724A1 (en) * 2004-06-08 2005-12-29 Decode Chemistry, Inc. 2,4-diaminoquinazolines for spinal muscular atrophy
EP3121176A1 (en) * 2004-06-08 2017-01-25 Families of Spinal Muscular Atrophy 2,4-diaminoquinazolines for the treatment of spinal muscular atrophy
US7888366B2 (en) 2004-06-08 2011-02-15 Families Of Spinal Muscular Atrophy 2,4-diaminoquinazolines for spinal muscular atrophy
AU2005254945C1 (en) * 2004-06-08 2013-07-11 Families Of Spinal Muscular Atrophy 2,4-Diaminoquinazolines for spinal muscular atrophy
AU2005254945B2 (en) * 2004-06-08 2012-11-08 Families Of Spinal Muscular Atrophy 2,4-Diaminoquinazolines for spinal muscular atrophy
EP2514748A1 (en) * 2004-06-08 2012-10-24 Families of Spinal Muscular Atrophy 2,4-diaminoquinazolines for spinal muscular atrophy
EP1852119A4 (en) * 2005-02-17 2008-05-28 Japan Science & Tech Agency Pharmaceutical composition containing phenoxazinium compound as active ingredient
EP1852119A1 (en) * 2005-02-17 2007-11-07 Japan Science and Technology Agency Pharmaceutical composition containing phenoxazinium compound as active ingredient
US8101760B2 (en) 2006-07-14 2012-01-24 Eli Lilly And Company Glucocorticoid receptor modulator and methods of use
US7985755B2 (en) 2006-08-01 2011-07-26 Families Of Spinal Muscular Atrophy 2,4-diaminoquinazolines for spinal muscular atrophy
US7994164B2 (en) 2007-12-19 2011-08-09 Eli Lilly And Company Mineralocorticoid receptor antagonists and methods of use
US8101761B2 (en) 2008-01-11 2012-01-24 Eli Lilly And Company (E)-N-{3-[1-(8-fluoro-11H-10-OXA-1-AZA-dibenzo [A,D] cyclohepten-5ylidene)-propyl]-phenyl}-methanesulfonamide as glucocorticoid receptor modulator for the treatment of rheumatoid arthritis
EP2470013A1 (en) * 2009-08-27 2012-07-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Compounds that treat malaria and prevent malaria transmission
EP2470013A4 (en) * 2009-08-27 2013-05-01 Us Health Compounds that treat malaria and prevent malaria transmission
US9375424B2 (en) 2009-08-27 2016-06-28 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Compounds that treat malaria and prevent malaria transmission
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
CN110526874A (en) * 2019-08-28 2019-12-03 武汉华星光电半导体显示技术有限公司 Fluorenes and phenazene derivative and preparation method thereof and OLED device
WO2022096990A1 (en) * 2020-11-05 2022-05-12 Cadila Healthcare Limited Novel hetrocyclic compounds

Also Published As

Publication number Publication date
EP1154997A1 (en) 2001-11-21
CA2361734A1 (en) 2000-10-12
US7056911B1 (en) 2006-06-06
JP2002541144A (en) 2002-12-03
EP1154997A4 (en) 2002-11-04

Similar Documents

Publication Publication Date Title
US7056911B1 (en) Dibenz[B,F]azepine compounds, pharmaceutical compositions comprising same and methods of use thereof
KR970009588B1 (en) Heterocyclic compounds
US6495688B2 (en) Deazapurine derivatives: a new class of CRF1 specific ligands
PL167097B1 (en) Method of obtaining enantiomeric analogues of purine nucleosides and method of obtaining novel pyrimidine derivatives
JP2005538992A (en) Kinase inhibitor
CZ223998A3 (en) 5H-THIAZOLO/3,2-a/PYRIMIDINE DERIVATIVE, PROCESS OF ITS PREPARATION, INTERMEDIATE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
HU219238B (en) Cyclic polyamines, process for producing them and pharmaceutical compositions containing the same
JP2005502662A (en) 1-alkyl or 1-cycloalkyltriazolo [4,3-a] quinazolin-5-ones as phosphodiesterase inhibitors
EP0220845A1 (en) Heterocyclic compounds and their preparation and use
HU217623B (en) Process for producing condensed thieno- and pyrrolo [3,2-c]pyridine-2-carboxylicacid derivatives and pharmaceutical compositions containing the same
EP2483274B1 (en) Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase
KR20000069827A (en) 3-ARYL SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF1) SPECIFIC LIGANDS
JP2018535261A (en) Heterocyclic compounds for the treatment of diseases
AU598878B2 (en) Quinoline base compound, process for the preparation thereof and anticancer agent containing the same as pharmacologically efficacious component
Rosowsky et al. 2, 4-Diamino-5-chloroquinazoline analogs of trimetrexate and piritrexim: synthesis and antifolate activity
US5008265A (en) 2-amino-7-(alicyclomethyl)-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
EP0809504A1 (en) Anti-viral triaza compounds
EP0021292A1 (en) Alkoxybenzylpyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
EP0004173B1 (en) 2,3-dihydroimidazo (1,2-c) pyrimidines, their preparation, formulations containing them and their use as pharmaceuticals
EP1057829B1 (en) Novel compounds and pharmaceutical compositions containing the same
US4581349A (en) Certain benzodiimidazoles and their use as radiation sensitizers
EP1023296A1 (en) 3-substituted pyrido 3&#39;,4&#39;:4,5] thieno 2,3-d] pyrimidine derivatives, and production and use of the same
JP2798628B2 (en) 5-Aminocarbonyl-5H-dibenzo [a, d] cycloheptene-5,10-imine for treating epilepsy
EP0238905B1 (en) 4-(2-pyrimidinyl)-1-piperazinyl heterocyclic carbonyl derivatives
WO1984004746A1 (en) Pyrimidine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2361734

Country of ref document: CA

Ref country code: CA

Ref document number: 2361734

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 609396

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000907039

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000907039

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09890112

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000907039

Country of ref document: EP